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Takayama - November 2009
The Takayama air gleams sparkling cold;
Strange autumn light streams through small maple leaves,
Which glow in glorious orange, red and gold,
While morning mist drips amongst ancient eaves.
The traveller wanders through Shinto shrines,
Whose columns echo the boldly tinted trees,
Matching red with red, each with each refines,
Defining mystic possibilities.
Then fracturing the silent tranquil scene,
The mountain river rumbles busily,
People bustle through old streets with old routine,
While time fumbles with eager certainty.
Yet 'neath the darkly glistening maple shades,
Serenity returns as chaos fades!
Prof. CL LAI
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Skin psoriasis is a chronic inflammatory cutaneous condition that is 
commonly encountered in clinical practice. This condition may 
sometimes be mistaken as eczema. In this issue, we will read about the 
various types of psoriatic lesions, the differential diagnoses and the 
available treatment options.
The impact of psoriasis on its sufferers is huge. Patients who have 
extensive skin involvement often have impaired quality of life. 
Stigmatisation is a central experience in these patients with broad 
psychological and social impact. Recognition of their psychological 
stress is essential as this may be linked to treatment non-compliance 
and hence worsening of status of the psoriasis. In this issue, we will 
also read about the psychosocial distress experienced by these patients 
and the ways to alleviate their psychological burden.
About one-third of patients with skin psoriasis may also have 
concomitant psoriatic arthropathy. These patients are commonly 
characterised by the presence of nail dystrophy. In this issue, we will 
read about the five clinical subtypes of psoriatic arthropathy. In those 
patients who present with rheumatoid arthritis pattern of joint 
distribution, the diagnosis of psoriatic arthropathy can be missed if 
the slightest attention has not been given to the tiny skin plaques over 
the extensor aspect of the elbows, over the nuchal region covered by 
long hair in girls and marks of post-inflammatory hyperpigmentation 
of treated skin lesions over the limbs. Radiological features such as 
periosteal bony proliferation, osteolysis and ankylosis often help in 
the diagnosis of psoriatic arthropathy. In this issue, we will learn how 
to interpret plain radiographic findings of psoriatic arthropathy and 
the use of various imaging modalities in the management of this 
disease and the associated musculoskeletal conditions.
Over a few decades, topical therapy including corticosteroids and 
keratolytics has been the conventional treatment of skin psoriasis. 
Phototherapy and systemic agents are reserved for patients with 
extensive disease. In this "biologic era" in the field of rheumatology, 
biologic therapies targeted against various inflammatory mediators 
with higher efficacy than conventional therapy are now available for 
the treatment of psoriasis and psoriatic arthropathy. In this issue, we 
will read about the efficacy and safety of anti-tumour necrosis factor-
alpha therapy and the recently available monoclonal antibodies 
against interleukin-12/interleukin-23 in the treatment of this disease, 
thus offering more hope to these patients.
Hope that you enjoy reading these articles.
Dr. PDr. Mo-yin MOK
Dr. Mo-yin MOK
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Psoriasis is a chronic skin condition which affects 2-3% 
of the population in Europe and the United States. 
Psoriatic arthritis (PsA) is an inflammatory arthritis 
associated with psoriasis. PsA is classified with the 
spondyloarthropathy (SpA) since these patients may 
present with spondylitis. However, other than the axial 
skeleton and the sacroiliac joints, PsA may also affect 
peripheral joints. PsA occurs in 6-39% of patients with 
psoriasis1 compared to the prevalence of 0.5-1% of 
rheumatoid arthritis (RA), a prototypic inflammatory 
arthritis that affects peripheral joints. Unlike RA that 
shows a female preponderance, the gender ratio among 
PsA patients was almost equal with peak age of disease 
onset between 30-40 years. 
Clinical Spectrum of PsA
Wright and Moll first described in 1876 the five patterns 
of PsA: (i) distal arthritis involving the distal 
interphalangeal (DIP) joints, (ii) oligoarthritis (<5 tender 
and swollen joints) involving small or medium-sized 
joints in an asymmetric distribution, (iii) a symmetric 
polyarthritis resembling RA, (iv) arthritis mutilans 
which is a deforming, destructive and disabling form of 
arthritis and (v) a SpA. Table 1 shows the reported 
frequency of different forms of PsA extracted from the 
largest cohort in the literature2. However, the joint 
pattern changes with time in over 60% of patients3 and 
these patterns may also overlap in patients with 
longstanding disease. 
dystrophy is the only clinical feature that can identify 
patients with psoriasis who will later develop arthritis. 
Nail lesions occur in around 90% of patients with PsA 
but only in 46% of psoriasis patients without arthritis4. 
Distal form of PsA
The distal pattern of PsA affects the DIP joints of the 
hands and can be very similar clinically and 
radiologically to erosive osteoarthritis of hands. DIP 
joint involvement in PsA is almost always accompanied 
by psoriatic nail changes of the corresponding finger. 
MRI scan revealed inflammation in the collateral 
ligaments, extensor tendons and entheseal insertions at 
the corresponding DIP joint with extracapsular contrast 
enhancement, bone oedema without cartilage damage 
and diffuse involvement of the nailbed in PsA5. The 
presence of psoriatic nail involvement is a clue to 
correct diagnosis of PsA clinically. X-rays may also help 
to differentiate between PsA and erosive osteoarthritis. 
The undulating osseous surfaces are usually closely 
applied in osteoarthritis while the lack of apposition of 
adjacent bony margins is a characteristic of PsA.
Oligoarticular form of PsA
The arthritis is inflammatory in nature and may show 
purplish red discoloration of the overlying skin, pain 
and significant early morning stiffness that improves 
with activity. Tenderness and joint effusion are usually 
less severe than in RA. The arthritis is typically 
asymmetric in distribution. Patients who initially 
presented with an oligoarthritis may later become 
polyarticular in disease involvement.
Polyarticular form of PsA
The polyarticular form of PsA may simulate RA. Table 2 
shows the clinical features that help to differentiate 
between these two conditions. PsA tends to be 
asymmetrical and peripheral joints are more commonly 
involved in the 'ray' pattern i.e. all the joints of a single 
digit are affected, in contrast to the 'raw' pattern in RA 
where the same joints on both sides are involved. This 
may also explain the tendency to asymmetry that occurs 
in about half the cases of polyarticular disease in PsA. 
The presence of erythema on the inflamed joint is 
unusual in RA but may be seen frequently in PsA 
probably reflecting exaggerated angiogenesis 
characteristics of psoriatic disease6. Positive serology for 
rheumatoid factor and anti-cyclic citrullinated peptide 
(CCP) antibodies, though more prevalent in 
Nail Dystrophy in PsA
The clinical features of the five patterns of PsA may also 
be found in other articular diseases. The presence of 
two or more features of onychopathy is in favour of a 
psoriatic origin for arthritis. Nail pitting is the most 
common psoriatic nail lesion while onycholysis, nail 
bed discoloration, subungual hyperkeratosis, transverse 
grooves or longitudinal ridging may be observed. Nail 
The Clinical Spectrum and Diagnosis of 
Psoriatic Arthropathy
Dr. Mo-yin MOK
Assistant Professor, Division of Rheumatology, Department of Medicine, Queen Mary Hospital
MBBS(HK), MRCP(UK), FHKCP, FHKAM, FRCP(Glas), FRCPA(Australia)
Dr. Mo-yin MOK
This article has been selected by the Editorial Board of the Hong Kong Medical Diary for participants in the CME programme of the 
Medical Council of Hong Kong (MCHK) to complete the following self-assessment questions in order to be awarded one CME credit 
under the programme upon returning the completed answer sheet to the Federation Secretariat on or before 31 May 2010.
Table 1. Distribution of different patterns of PsA from a 
cohort of 2202
Joint pattern of PsA
   Distal interphalangeal joints
   Oligoarthritis
   Polyarthritis
   Spondyloarthritis
   Arthritis mutilans
Percentage
12
14
40
2
16
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RA, may be found in 10-15% of PsA patients7. 
Radiologically both PsA and RA are characterised by 
osseous erosions, however, irregular excrescence of 
bony proliferation and lack of juxta-articular 
osteoporosis strongly favour diagnosis of PsA. 
Psoriasis and RA may coexist with a prevalence of 
3:10000, the presence of nail dystrophy helps to 
distinguish patients with PsA from those with RA and 
psoriasis. In 7-30% of patients, arthritis may precede the 
appearance of psoriatic skin lesions and is referred to as 
"PsA sine psoriasis"8. In these patients, correct diagnosis 
of PsA will depend solely on the recognition of specific 
features of the articular disease. 
Spondyloarthropathy of PsA
PsA is classified with the SpA because of the presence 
of spondylitis in up to 40% of patients, other features of 
SpA (inflammatory enthesopathy, dacylitis, periosteal 
proliferation), the occurrence of extra-articular features 
common to the SpA (mucous membrane lesions, iritis, 
urethritis, diarrhoea, aortic root dilatation) and 
association with HLA-B27. The frequency of spinal 
involvement in PsA has been reported to be 2% as an 
isolated back disease to as high as 40% when associated 
with peripheral arthritis. 
There is gender difference in disease expression among 
PsA patients with more advanced SpA among men. 
PsA patients who have spinal involvement are usually 
older than those without back involvement.Patients 
with SpA may present with inflammatory back pain 
and stiffness with restricted range of movement of the 
back. Clinical signs suggestive of sacroiliitis can be 
elicited from physical examination. PsA patients with 
SpA are mostly asymptomatic, are detected 
radiographically and may demonstrate full range of 
back movement. Compared to patients with ankylosing 
spondylitis, there is usually less severe neck pain and 
back pain, less limitation of movement and grade 4 
sacroiliitis in PsA patients. PsA is characterised by the 
relative asymmetry of sacroiliac/spinal involvement and 
more extensive paramarginal syndesmophytes and/or 
periosteal reaction compared to ankylosing spondylitis 
or SpA related to inflammatory bowel disease. Cervical 
spine disease is found in 70% of PsA patients. 
Atlantoaxial subluxation is reported in 23% of patients 
and is related to prolonged disease duration.
Arthritis Mutilans
Arthritis mutilans is a destructive form of PsA and may 
lead to extensive and irreversible joint damage with 
appearance of the "telescoping" phenomenon and 
shortening of the digits within a short time (Figure 1). 
Severe joint or bone lysis leads to deformities with 
shortening and telescoping of digits.
Enthesitis
The clinical presentation and radiological features of the 
oligoarticular and spinal patterns of PsA are similar and 
are often difficult to distinguish from other members of 
the SpA group such as reactive arthritis and 
inflammatory bowel disease related SpA. Enthesopathy, 
inflammation at the sites of tendon insertion, is 
particularly prominent in PsA affecting more frequently 
the plantar fascia or Achille's tendons. Enthesitis may be 
recognised radiographically as spurs and may also be 
identified using ultrasound scan. MRI scan reveals bone 
marrow oedema adjacent to the entheseal insertion sites 
representing a synovioentheseal inflammatory complex 
at the very early stage of PsA9 corroborating the enthesis-
based biomechanical hypothesis of disease pathogenesis. 
Dactylitis 
Dactylitis or 'sausage digits' is a typical feature of PsA 
(Figure 1) which presents as swelling of a whole digit 
with inflammation involving the distal and proximal 
i n t e r p h a l a n g e a l  a n d  o c c a s i o n a l l y  t h e  
metacarpophalangeal joints may be seen in 16-48% of 
patients. Dactylitis is usually less common in other SpA. 
MRI scan reveals features of synovitis with extensive 
inflammation and effusion in all the joints of a 
particular digit with an associated tenosynovitis in the 
whole digit and has been suggested to be a marker of 
disease progression in PsA10. 
Extra-dermal Extra-articular Features
Extra-articular manifestations of PsA are different from 
those of RA. Rheumatoid nodule is not found in PsA. 
Rheumatoid factor is present in around 10-15% of PsA 
patients compared to 70-80% of RA patients. Other extra-
dermal, extra-articular features of PsA include iritis (7%), 
mouth ulcer, urethritis, colitis and aortic valve disease 
giving rise to morbidities in these patients. 
Table 2. Comparison of clinical features between PsA and RA. 
Demographics
   Peak age at presentation (years)
   Female preponderance
Clinical characteristics
   Distal interphalangeal joint involvement
   Symmetry
   Erythema over affected joints
   Spondylitis
   Enthesopathy
   Skin lesions
   Nail lesions
Extra-articular manifestations
   Rheumatoid nodule
   Aortic valve disease/aortitis
   Eye involvement
Serological features
   Rheumatoid factor
   Anti-cyclic citrullinated peptide antibody
   Elevation in level of erythrocyte 
sedimentation rate / c-reactive protein
Radiological features
   Osteopenia
   Osteolysis
   Ankylosis
PsA
30-40
Uncommon
Common
Less common
Common
Common
Common
Common
Common
Not present
Present
Iritis, uveitis
Uncommon
Uncommon
Lesser extent
Uncommon
Common
Common
RA
40-60
Common
Uncommon
Common
Uncommon
Uncommon
Uncommon
Uncommon
Uncommon
Present
Not present
Scleritis, 
episcleritis
Common
Common
Greater extent
Common
Uncommon
Uncommon
Figure 1. Telescoping of big toe and dactylitis of the second toe 
in a patient with PsA.
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Diagnosis of PsA
There are no specific laboratory tests which are 
diagnostic for PsA. Blood investigations may show 
anaemia of chronic illness or iron deficiency anaemia 
secondary to therapy with non-steroidal anti-
inflammatory agents. Acute phase reactants in PsA are 
frequently normal or minimally elevated contributing 
little to diagnosis and may also be present in psoriasis 
patients without arthritis. Hyperuricaemia is not 
uncommon and is related to turnover of skin cells. 
Rheumatoid factor is usually negative but 10-15% of 
patients may have positive rheumatoid factor in low 
titre which is also present in similar proportion of 
patients without arthritis. Typical radiological features 
of PsA include pencil-in-cup appearance, irregular 
periosteal bone proliferation, resorption of the distal 
tuft and ankylosis and are diagnostic of the condition11.
The diagnosis of PsA can be established in patients with 
an inflammatory arthritis who present with pre-existing 
skin psoriasis. Sometimes the skin lesions may be 
minimal and efforts should be made to look for skin 
lesions in the umbilical area, anal cleft, scalp and the 
ears. For patients who do not have skin lesions, the 
clinical radiographic features such as fluffy periostitis, 
lysis of terminal phalanges, pencil in cup appearance, 
gross destruction of isolated joint, ankylosis, and 
spondylitis may assist in diagnosis. The absence of 
juxta-articular osteoporosis, lack of symmetry and 
predilection for distal interphalangeal joints make RA 
less likely. The presence of dactylitis and enthesitis are 
more suggestive of PsA. Iritis and mucous membrane 
lesions may be more common in Reiter's disease. 
The CASPAR Criteria
Historically, the Moll and Wright criteria have been 
used for the classification of PsA12. An international 
group of experts on PsA, the ClASsification of Psoriatic 
ARthritis (CASPAR) study group, has developed a new 
classification scheme (Table 3) based on extensive 
analysis on 588 patients with PsA and 534 other 
inflammatory arthritis has shown a specificity of almost 
99% and sensitivity of 91.4%13. The CASPAR criteria are 
progressive by permitting the diagnosis of PsA sine 
psoriasis as well as in rheumatoid factor positive 
patients. 
Clinical Course of PsA
It has always been believed that PsA is less aggressive 
compared to RA. However, destructive deforming 
arthritis has been reported in about 20% of PsA 
patients8. Radiological erosion was observed in 47% of 
patients within 2 years of disease onset and 55% 
patients have five or more deformed joints upon follow 
up for over 10 years3. 67% of established PsA patients 
had erosive disease in the clinic setting14. HLA antigens 
including HLA-B27 in the presence of HLA-DR7, HLA-
B39 and HLA-DQw3 in the absence of HLA-DR7 were 
predictive of subsequent damage15. Clinical predictors 
for disease progression were found to include > 5 
swollen joints, high medication level particularly use of 
steroids at presentation to the clinic and female 
gender16. Other than its impact on functional status, 
patients with PsA also had impaired level of quality of 
life similar to patients with RA17. PsA patients were also 
found to be more predisposed to have accelerated 
atherosclerotic vascular disease18. The impact of PsA is 
also reflected by the increased mortality with a 
standardised mortality ratio of 1.62 with frequent 
cardiovascular deaths19. 
Table 3. CASPAR classification of psoriatic arthritis13
Established inflammatory musculoskeletal disease (joint, spine or entheseal)
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MCHK CME Programme Self-assessment Questions
Please read the article entitled "The Clinical Spectrum and Diagnosis of Psoriatic Arthropathy"  by Dr. Mo-yin MOK 
and complete the following self-assessment questions. Participants in the MCHK CME Programme will be awarded 1 
CME credit under the Programme for returning completed answer sheets via fax (2865 0345) or by mail to the 
Federation Secretariat on or before 31 May 2010. Answers to questions will be provided in the next issue of The Hong 
Kong Medical Diary.  
1. Which condition is more prevalent in the general population?
a. Skin psoriasis
b. Rheumatoid arthritis
c. Spondyloarthropathy form of psoriatic arthropathy
d. Distal pattern of psoriatic arthropathy
2. Which of the following best classify psoriatic arthropathy ?
a. Connective tissue disease
b. Rheumatic manifestations of systemic diseases
c. Spondyloarthropathy
d. Reactive arthritis
3. The following are typical clinical patterns of psoriatic arthropathy except
a. Symmetrical polyarthritis
b. Asymmetrical oligoarthritis
c. Spondylitis
d. Atlantoaxial subluxation
4. The following features are present in psoriatic arthropathy sine psoriasis except
a. Skin psoriasis  
b. Nail dystrophy
c. Dactylitis
d. Enthesitis
5. Which of the following extra-articular features is found in psoriatic arthropathy?
a. Rheumatoid nodule
b. Interstitial lung disease
c. Aortic valve disease
d. Scleromalacia perforans
6. The following features favour psoriatic arthropathy over rheumatoid arthritis except
a. Dactylitis
b. Enthesitis
c. Periungal erythema
d. Nail dystrophy
7. Compared to ankylosing spondylitis, the spondyloarthropathy of psoriatic arthritis is
a. More extensive in involvement
b. Less severe in symptoms
c. More symmetrical in involvement
d. More frequently associated with HLA-B27
8. Which of the following statement in regard to enthesitis is incorrect?
a. is inflammation of tendon insertion
b. may be detected by ultrasound scan
c. may show up as spur on plain X-ray
d. represents tenosynovitis and arthritis of the involved digit
9. The following are typical radiological features of psoriatic arthropathy except
a. Juxta-articular osteoporosis
b. Pencil-in-cup appearance
c. Lysis of terminal tuft
d. Unilateral sacroiliitis
10. The following are predictive factors for progression of psoriatic arthropathy except
a. Dactylitis
b. High level of medication at initial presentation to clinic
c. Male gender
d. Extensive joint involvement at disease onset
Questions 1-10: Please choose the best answer.
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The Clinical Spectrum and Diagnosis of Psoriatic Arthropathy
Please return the completed answer sheet to the Federation Secretariat on or before 31 May 2010 for 
documentation. 1 CME point will be awarded for answering the MCHK CME programme (for non-specialists) 
self-assessment questions. 
 Name (block letters):____________________________________ HKMA No.:
HKDU No.:
DCHK No.:
 
 ___ ___ - ___ ___ ___ ___ X  X  (x)HKID No.:
______ ______ ______________________
 ____________ ______________________
 ____________ ______________________
  
Contact Tel No.:_________________________________________________
ANSWER SHEET FOR MAY 2010
Answers to April 2010 Issue
Facial Plastic Surgery in Otorhinolaryngology
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Dr. Mo-yin MOK
Assistant Professor, Division of Rheumatology, Department of Medicine, Queen Mary Hospital
MBBS(HK), MRCP(UK), FHKCP, FHKAM, FRCP(Glas), FRCPA(Australia)
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Introduction 
Definition
Psoriasis is one of the prototypic papulosquamous skin 
diseases characterised by erythematous papules or 
plaques with silvery scales. It is a chronic inflammatory 
skin disease with increased epidermal proliferation 
related to dysregulation of the immune system. 
Epidemiology
Psoriasis is said to affect 2% of the world population. The 
prevalence is up to 5% in selected Western population. 
The prevalence in Chinese is estimated to be 0.3% to 
slightly more than 1%, the variation in estimation is 
accounted for by the methodological differences in these 
surveys. 
Psoriasis has a bimodal age of disease onset. The first 
peak is around 20 and the second peak is around 60. 
People with disease onset around 20 year old have 
stronger genetic predisposition. They have a higher 
prevalence of having HLA-Cw6. The linkage to genetic 
factor is lower for the group with late onset disease. 
Pathology and Pathogenesis
Pathology
The pathology of an established lesion of psoriasis is 
characterised by epidermal hyperplasia with squared-off 
rete ridges, parakeratosis, elongation of dermal papillae 
with thinning of the supra-papillary epidermis, dilated 
tortuous capillaries and perivascular lymphohistiocytic 
infiltration of the superficial dermis. In some of these 
lesions, collection of polymorphonuclear cells in the 
stratum corneum (known as Munro microabscess) and 
between keratinocytes (known as spongiform abscess of 
Kogoj) may be found. 
Pathogenesis
The cell cycles of the epidermal cells in psoriatic lesions 
are greatly accelerated. Turnover of the basal cells, which 
divide every 1.5 days, in psoriatic skin is as fast as the 
rapidly growing cells of the small intestinal mucosa. The 
epidermal transit time is shortened from the normal 28 
days to as short as 3-4 days. Such a change in epidermal 
cell cycle is thought to be related to the inflammatory 
cytokine released in the inflammatory process. Psoriasis 
is considered to be a prototypic Th1 disease. Increased 
amounts of Th1 cytokines viz interferon  and IL-2 are 
observed. Early interventional researches adopted drugs 
such as cyclosporine A with pharmacological effects on 
this pathway, rendered proof of concept evidence to this 
observation. Studies have also demonstrated that 
keratinocytes and dendritic cells play an important role 
in innate and adaptive immune response of the skin. The 
innate immune response cytokines IL-1, 6 and TNF   are 
up-regulated in psoriatic skin. Biologic approaches to 
reduce the activity of TNF  are found to be useful in 
psoriasis. Recent studies show that Th17 cells, a novel 
subset of T cells, play a pivotal role in the pathogenesis of 
psoriasis. Recognition of the early dendritic cell-T cell 
interaction through IL-12 and IL-23 provides the new 
insight for the latest biological treatment, the monoclonal 
antibody against IL-12/IL-23, which results in a 
breakthrough in the management of psoriasis1. 
Clinical Features 
Prototypic lesion
The typical lesion of psoriasis is a well-demarcated 
erythematous plaque with silvery scales on top of the 
plaque (figure 1). The affected patient may experience 
itchiness. The plaques may affect anywhere of the skin 
surface but the mucosa is normally spared. The scales 
may only be loosely attached and easily fall off from the 
skin. The disease may wax and wane, and not 
uncommonly is aggravated by trauma and irritation, 
infections, various drugs, seasonal changes and 
psychogenic stress. 
Abbreviation used:
HLA : human leucocyte antigen
Th1 : type I helper T cell
IL : interleukin
TNF : tumour necrosis factor
PASI : psoriasis area and severity index
BSA : body surface area
DLQI : dermatology life quality index
UV : ultraviolet light 
PUVA : ultraviolet A with psoralen therapy
Psoriasis
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Figure 1. Stable plaque psoriasis: well-demarcated erythematous 
plaque with a silvery scale on top.   
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Chronic Stable Plaque Psoriasis
Sites of predilection of the characteristic plaques include 
the extensor surfaces of the elbows, knees, lower back 
and scalp. The genitalia and nails may also be affected. 
The plaques vary in size (figure 2). New lesions may be 
induced at traumatised skin such as surgical scar, or 
even scratch marks (known as Kobner phenomenon). 
Differential Diagnosis
Common conditions that may present as erythematous 
plaque include discoid eczema, lichen simplex chronicus, 
hypertrophic lichen planus and Bowen's disease. 
Guttate Psoriasis
It is a variant characterised by small coins or even 
punctate lesions with less amount of scale affecting 
mostly young people. The disease may be precipitated by 
upper respiratory tract infection. Over half of these 
patients have some evidence of preceding streptococcal 
infection. A few may have prolonged disease remission 
after the acute episode. 
Differential Diagnosis
Common conditions that may present as guttate 
papulosquamous lesions include pityriasis rosea, 
secondary syphilis and pityriasis lichenoides. 
Unstable Psoriasis
Lesions are angry looking with more intense 
inflammation. These may be redder in colour with less 
scaling. Lesions may be less well-demarcated and 
occasionally exudation and crust are found2. Patients 
may experience more itchiness, irritation and even pain. 
Further progression to erythrodermic or pustular 
psoriasis can happen. Inappropriate use of 
corticosteroids, excessive irritation, sunburn are some of 
the factors not uncommonly associated with unstable 
psoriasis.
Differential Diagnosis
Common conditions that may present like unstable 
psoriasis include eczema and tinea incognito. 
Erythrodermic Psoriasis
When more than 90% of the body is involved by 
psoriasis, it is defined as erythrodermic psoriasis. An 
affected patient is characterised by having generalised 
redness of skin and scaling. The colour may sometimes 
be described as dusky red. The face may occasionally be 
relatively spared. Individual plaques may not be 
obvious. Pustules may sometimes be found. Triggering 
factors are not uncommonly unidentified. Affected 
patients may have systemic symptoms. 
Differential Diagnosis
Conditions that may present as erythroderma include 
eczema/dermatitis, cutaneous T cell lymphoma, drug 
reaction, pityriasis rubra pilaris and pemphigus 
foliaceus. 
Pustular Psoriasis
Tiny superficial pustules with a background of erythema 
may occur. The roof of the pustules is easily broken. 
These pustules can be distributed throughout the whole 
skin surface or more localised especially in and around 
the unstable lesions. Some patients may have lesions 
with matted scales with a yellowish hue and if biopsy of 
these lesions is performed, the histology shows sheets of 
subcorneal polymorphs. Though very discrete pustules 
may not be seen clinically, these lesions may be described 
as pustular psoriasis by some clinicians. Steroid 
withdrawal* is the commonest precipitating factor 
encountered by the author as the cause of pustular 
psoriasis. Localised pustular psoriasis on the palms and 
soles is reported to be associated with smoking. 
Differential Diagnosis
Conditions that may present as generalised pustulosis 
include infections, acute generalised exanthematous 
pustulosis and subcorneal pustular dermatosis.
*Not only when systemic steroids are given and tapered, 
but also when the patient has used super potent topical 
steroids for a long time, therefore, save for a few 
exceptional clinical situations, systemic steroids are 
contraindicated in psoriasis.
Psoriasis in Specific Body Locations
Scalp and face: The scalp is one of the most common 
sites affected by psoriasis. The typical plaques may 
extend slightly beyond the hairline (figure 3). Patients 
may present as recalcitrant dandruff. Some may involve 
the glabella region, eyebrows, and nasolabial fold, and in 
this situation it merges with seborrhoeic dermatitis. The 
term sebopsoriasis is coined to describe these cases. The 
external auditory canal is not uncommonly affected. 
Psoriatic lesions on the face may not be very well-
demarcated nor is the silvery scale easily discernible. 
Figure 2. Diffuse involvement of the back in this patient. If 
more than 90% of the body surface is affected, it is referred as 
erythrodermic psoriasis.
Figure 3. Psoriasis of the scalp. Lesion not uncommonly 
extends beyond the hairline. Psoriatic lesion on the face may 
not be very well-demarcated nor is the silvery scale easily 
discernible.
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Differential Diagnosis
Conditions that may mimic psoriasis on the face or 
scalp include seborrhoeic dermatitis, lichen simplex 
chronicus (plaques on scalp) and tinea capitis. 
Flexural regions: Lesions located at the axillae, 
inframammary folds, groins, intergluteal cleft and 
prepuce of the uncircumcised may present as shiny 
pink to red thin plaques or even patches. Fissure may 
sometimes be present. The scale is not discernible. 
Itchiness and irritation are not uncommon. The term 
inverse psoriasis is coined to describe these lesions. 
Differential Diagnosis
Conditions that may mimic psoriasis in the 
intertriginous areas include seborrhoeic dermatitis, 
candida infection, intertrigo and extramammary Paget's 
disease. 
Nail: Nail involvement has been reported in 10 - 80% 
of patients with psoriasis (figure 4). Features include 
onycholysis with or without the oil drop phenomenon, 
distal subungual hyperkeratosis, thimble pitting, 
crumbly poorly adherent nail, loss of lustre among 
other changes. The finger and toe nails can be affected. 
Patients with nail involvement may have a higher 
incidence of arthropathy. Psoriatic nails may also 
predispose to fungal infection. Nail disease can cause 
much concern to those affected because it can be 
symptomatic, have functional disability, cosmetically 
unacceptable but otherwise recalcitrant to all forms of 
treatment. 
Disease Assessment
Clinician Based
The British guidelines define "severe" disease as PASI 
score of 10 or more (or a BSA of 10% or greater where 
PASI is not applicable) and a DLQI > 10, i.e. the rule of 
ten proposed by Finlay3. PASI and BSA are regarded as  
clinician-based assessment of severity. In recent years, 
patient reported outcome such as health related quality 
of life assessment by various tools is required by the 
Differential Diagnosis
Conditions that may mimic changes in nail psoriasis 
include fungal infection and various forms of idiopathic 
nail dystrophy. 
Clues to differentiate these conditions are summarised 
in table 1. Psoriatic arthropathy is discussed in another 
article of this issue. 
Dr. King-man HO  
Figure 4. Nail psoriasis. Onychomycosis seldom presents 
as symmetrical involvement of the finger nails especially 
when all ten nails are  involved.  The unhealthy nails are 
more prone to secondary fungal infection and therefore 
should be excluded as appropriately.  
Table 1. Differential diagnosis and clinical clues to guide 
differentiation
Psoriasis 
presentation
Stable plaque
Guttate
Unstable
Erythrodermic
Pustular
Scalp
Inverse
Nail
Eczema (discoid and 
chronic lichenified)
Hypertrophic lichen planus
Bowen's disease
Pityriasis rosea
Secondary syphilis
Pityriasis lichenoides 
chronicus (PLC)
Eczema
Tinea incognito
Other causes of 
erythroderma such as 
eczema/dermatitis, 
cutaneous T cell lymphoma, 
drug reaction, pityriasis 
rubra pilaris (PRP), 
pemphigus foliaceus.
Generalised: acute 
generalised exanthematous 
pustulosis
Subcorneal pustular 
dermatosis
Localised palmoplantar 
pompholyx; tinea pedis
Seborrhoeic dermatitis
Tinea capitis
Candidiasis
Tinea 
Extramammary Paget's 
disease
Onychomycosis
Differential diagnosis
Weeping in active discoid 
eczema; lichenification in lichen 
simplex, scales in lichen simplex 
are not as loosely attached and 
silvery as in psoriasis
Violaceous plaques mostly 
located on the shins, scales are 
not as loosely attached and 
silvery
Long standing solitary thin 
plaque without the characteristic 
silvery scale in psoriasis
Oval papulosquamous plaques 
with long axis of lesions aligned 
in a fir tree distribution mostly 
on the trunk
Palm and sole involvement, 
mucosal lesions, systemic 
symptom, lymphadenopathy
More polymorphic in PLC, mica 
scale and Oblaten sign
Among the unstable psoriatic 
lesions, some may have 
otherwise typical morphology of 
psoriasis; history of using potent 
topical steroid or systemic 
steroid
Less plaque like and angry 
looking in tinea incognito
History of psoriasis; nail 
changes of psoriasis; history of 
eczema or exposure to allergens; 
painful keratoderma, diffuse 
alopecia and leonine face in T 
cell lymphoma; starts as 
morbilliform rash in drug 
reaction; island of sparing, 
perifollicular erythema and 
orange hue in PRP; impetigo- 
like blisters and erosions 
followed by collarettes of scale 
or scale-like crusts in pemphigus 
foliaceus
Sudden onset after taking drug; 
no past history of skin diseases; 
self limited 
Predilection for axillae and 
around the groins
Vesicular lesions instead of 
pustular lesions
Discernible plaque or patch in 
psoriasis
Bald patches in tinea with 
broken hair stump
Satellite lesions with scalloped 
scale in candida intertrigo
Faintly discernible active margin 
in tinea
More wet looking and with 
erosion in extramammary 
Paget's disease
Chalky white subungual 
hyperkeratosis or superficial or 
proximal subungual whitish 
discolouration; the oil drop sign 
and thimble pitting in nail 
psoriasis
Clinical differentiation
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regulatory agencies for drug registration. DLQI and SF- 
36 are two of such instruments commonly used in clinical 
trials in psoriasis. PASI 75, which refers to a reduction of 
PASI score by 75% of the baseline, is employed as an 
endpoint assessment in modern clinical trials involving 
biologics. PASI is calculated as follows:
   [area score of the region X extent indicator of the region 
X (sum of severity indicator of the region)]
= 0.1 AHead (E + S+ T) + 0.2 AUpper limbs (E + S+ T) + 0.3 
ATrunk (E + S+ T) + 0.4 ALower limbs (E + S+ T) wherein A 
refers to area of the suffix region according to a 7-point 
scale (0-6), E, S, T refers to the degree of erythema, 
scaling and thickness respectively according to a 5-point 
scale (0-4). The maximum score is 72. 
Severity assessment of joint disease is discussed in the 
other chapter of the same issue.
Other Assessment
The occupation history is also important as this will 
give an idea of the social and functional disability 
associated with the skin condition of the index patient. 
Treatment and drug history will provide further 
information guiding the choice of various therapeutic 
modalities for a particular patient. 
As a routine, the author also asks the patient how 
he/she feels about his/her skin disease and what his/her 
major concern is before the discussion of the various 
treatment options. 
Laboratory investigations are not required in an 
otherwise simple and mild case of psoriasis. Skin biopsy 
is not usually required to establish the diagnosis of 
psoriasis unless in doubt. Skin scraping, hair plugging 
or nail clipping for fungal study may be performed as 
appropriate. If systemic therapy or phototherapy is 
contemplated, baseline investigations include complete 
blood picture, liver and renal biochemistry, hepatitis 
serology, anti-nuclear antigen, fasting sugar and lipid, 
and chest X-ray should be performed to guide choosing 
a preferred modality from the various possible options.
Recent epidemiological studies also reveal that people 
with psoriasis are associated with risk factors for 
cardiovascular diseases, table 24. Although standard 
guidelines for screening of cardiovascular risk factors 
have not arrived, to take a good history covering these 
risk factors such as smoking habit, personal and family 
history of diabetes, hypertension, hyperlipidaemia and 
cardiovascular diseases may be contributory to the 
holistic management of a person with psoriasis. The 
affiliated service of the author also recommends routine  
measurement of the body mass index and blood 
pressure in patients newly presented with psoriasis. 
Management
The Principle of Management 
To understand the expectation of the patient is the most 
important first step in management. To communicate 
and educate the index case is the next important step. 
Appropriate skin care, avoidance of aggravating factors, 
the importance of keeping a good treatment history, 
cessation of smoking, avoidance of excessive alcohol 
drinking, reinforcement of the non-contagious nature 
and chronicity of the condition and conveying the 
message that psoriasis is amenable to very good control 
are the important contents in communication, especially 
in the first few encounters. Instruction on using 
especially the perplexing large number of topical drugs 
should be simple and clear. Printed information is 
invaluable. 
Treatment Options
Treatment for psoriasis can be classified as:
Management Hierarchy
A combination of topical therapies is usually used as 
the first line treatment in patients with limited area 
involvement i.e. <10-20% BSA. If the condition is not 
under satisfactory control by topical therapy or the 
disease is too extensive, phototherapy or systemic 
therapies may be considered. Poor adherence to topical 
therapy is not uncommon. Therefore, before 
considering systemic treatment, skillful counselling is 
almost a must not only to confirm poor adherence, but 
also to know the expectation and concern of the patient. 
In a patient who has severe disease (c.f. the 
aforementioned rule of ten) which fails phototherapy 
and systemic therapy, or who is intolerant to these 
therapies, or who has significant, coexisting 
comorbidity (e.g. significant impairment of renal or 
liver function and unable to attend 2x/week for 
phototherapy in a designated dermatology clinic) which 
precludes the use of these treatments, biologic therapy 
can be considered5. 
As the adverse effects of these treatments differ or 
overlap one another, and some of these treatments have 
Topical drugs: topical steroids, vitamin D analogues, 
tar, dithranol (which may have been withdrawn from 
the local market), keratolytics, calcineurin inhibitors, 
tazarotene (vitamin A analogue which is not 
available in the local market)
UV light therapy: UVB including nBUVB, PUVA, 
targeted phototherapy such as UVB delivered with 
the laser system (Excimer   308 nm)
Traditional systemic therapy: methotrexate, 
systemic retinoid, cyclosporine A, (others include 
hydroxyurea, 6-thioguanine, mycophenolate mofetil, 
fumaric acid esters, these are less extensively used 
and their use is regarded off-label by the 
manufacturers, fumaric acid esters are not available 
in the local market)
Biologic therapy:  etanercept,  infl iximab,  
adalimumab which target TNF   ; ustekinumab which 
targets IL-12 & 23
1.
2.
3.
4.
 
Table 2. Prevalence of diseases associated with metabolic 
syndrome (WHO case definition) in patients with psoriasis 
(Cohen et al. 2008)
Category Prevalence
Psoriasis
n = 16 850
Control
n = 48 677
OR (95% CI)
Mean age, years (SD)
Ischaemic heart disease % (n)
Diabetes mellitus % (n)
Hypertension % (n)
Obesity % (n)
42.7 (20.3)
14.2 (2 387)
13.8 (2 324)
27.5 (4 627)
8.4 (1 419)
51.0 (19.1)
7.1 (3 479)
7.3 (3 556)
14.4 (7 017)
3.6 (1 768)
2.1 (2.0-2.3)
2.0 (1.9-2.1)
2.2 (2.2-2.3)
2.4 (2.3-2.6)
SD = standard deviation; CI = confidence interval; OR = odds ratio
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Conclusion
Psoriasis is a chronic inflammatory skin disease which 
causes significant functional impairment to those 
affected. A constellation of treatments is now available
which can achieve disease control in most people with 
psoriasis. The best available evidence in management 
should, however, be applied on an individual basis. 
recommended ceiling cumulative exposure such as not 
more than 150 to 200 treatment sessions in PUVA, 
treatment rotation is not uncommonly adopted. For 
recalcitrant cases, a combination of systemic including 
biologic therapies may be used. A failure of treatment 
with one biologic does not necessarily mean knocking 
out the whole group of biologics. The strength and 
weakness is summarised in table 3.
Table 3. Highlights and comparison of treatments for psoriasis 
Treatment
Topical
Steroids
Vit D analogues
Tar
Others
Phototherapy
Systemic
Methotrexate
Systemic retinoid
Cyclosporine A
Biologics
Still the mainstay of topical treatment
A wide variety of choice with respect to 
potency and formulations; the most potent 
is more than 600 times the least one
No more than twice daily use 
recommended
Co-formulated with other active 
ingredients such as calcipotriol, salicylic 
acid
Calcipotriol; calcitriol
Calcipotriol is co-formulated with 
betamethasone dipropionate
May be used during the steroid drug 
holiday 
Commonly used for bathing, though gel 
formulation for direct application is 
available
Combined with phototherapy in the classic 
Goeckerman regime
Dithranol is not available in the local 
market
Calcineurin inhibitors can be used to treat 
facial and flexural psoriasis
Sulphur and salicylic acid are commonly 
used as de-scaling agents but seldom used 
alone
These include UVB (broad or narrow 
band); PUVA; targeted phototherapy
Weekly dosing with dose ranges from 5 
mg to 25 mg
Commonly dosed together with folate 
supplement
Acitretin is the retinoid of choice in 
psoriasis
Dose seldom exceeds 1 mg/kg/day
2.5 to 5.0 mg/kg/day;
 
Etanercept, infliximab and adalimumab 
target TNF
Ustekinumab targets IL 12 & 23   
Available in the local market
Apart from infliximab which is delivered 
by intravenous route, the others can be 
given subcutaneously
Effective & user friendly
The main non- steroidal topical preparation
No evidence for tachyphylaxis
Non-steroidal topical preparation
Treatments do not have substantial systemic 
adverse effects
PUVA is a very effective treatment
UVB therapy can be use in pregnancy 
  
Convenient, user friendly
Effective, inexpensive traditional systemic 
treatment
Long experience
Can be used in a variety of psoriatic state
  
Long experience
Very effective when  combined with PUVA
Severe acute adverse event uncommon
Not usually hepatotoxic
May be effective in arthritis
Neither toxic to the liver nor to the kidney in 
contrast to the conventional systemic drugs
Dosing can be spaced out e.g. quarterly dose 
of ustekinumab is required after the initial 
induction
Effective in arthropathy
Tachyphylaxis dissociated with adverse effects
Systemic effects after prolonged use of potent 
topical steroids
Caution: use on the face and intertriginous 
regions; use of super potent topical steroid in 
unstable psoriasis
Not all patients like vit D analogues because of 
irritation and less quick in action compared to 
topical steroids
Caution: maximum weekly amount 100 gm for 
calcipotriol (210 gm for calcitriol)
Not user friendly because of its smell and 
appearance
Caution: use in unstable psoriasis
Patient needs to present personally to the clinic 
for treatment 2-3x weekly
Patient needs to wear glasses that filter UV light 
for the whole day after PUVA
Less than 150-200 lifetime cumulative exposure 
is recommended for PUVA
Not suitable for unstable, erythrodermic, or 
pustular psoriasis
Idiosyncratic reaction leading to pancytopaenia, 
paradoxic skin necrosis, hence,slow incremental 
dosing is commonly adopted
Teratogenicity and effect on male fertility
In real life situation it may be difficult to use as 
so many people may have deranged liver 
function such as fatty liver
Seldom achieves very satisfactory disease 
control
Fair patient acceptability because of 
constellation of minor adverse effects
One of the most potent teratogen known; in 
female, written consent is required by the 
manufacturer
Extensive drug interaction with a variety of 
drugs
Seldom used for more than 2 years because of its 
nephrotoxicity
Relapse is common upon treatment cessation
Apart from adverse effects such as 
demyelinating disease, proneness to infections of 
which TB is of most concern
Induction of ANA positivity
Long term adverse effects are unknown 
Short notes for Practical use Strength Weakness
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Introduction
Psoriatic arthritis is a distinctive kind of arthritis in 
patients with psoriasis. This disorder has a wide 
radiological spectrum and should be recognised at early 
stage of the disease. The presence of articular 
abnormalities in psoriatic patients varies from 2% to 6%. 
The reported prevalence of psoriasis among patients 
with polyarticular arthritis ranges from 3% to  5%.1  Five 
varieties of psoriatic arthritis have been categorised by 
the work of Wright and Moll.2,3 They include 
polyarthritis with distal interphalangeal joint 
involvement; symmetrical seronegative polyarthritis 
simulating rheumatoid arthritis; monoarthritis or 
asymmetrical oligoarthritis; sacroiliitis and spondylitis; 
and arthritis mutilans.  In certain cases, the diagnosis of 
psoriatic arthritis cannot be made solely based on 
radiological findings. Some patients have disease 
patterns that differ from the five classical types. In one 
group of patients, dactylitis or enthesitis are the 
predominant abnormalities.4 
Typical Sites of Radiological 
Abnormalities
Psoriatic arthritis involves the synovial and cartilaginous 
joints, as well as the attachment of tendons and ligaments 
to the bones in the appendicular and axial skeleton.  It 
shows similar distribution of abnormalities as Reiter's 
syndrome and ankylosing spondylitis, and differs from 
rheumatoid arthritis.
The most typical sites of abnormalities are the 
interphalangeal joints of hands and feet,  
metacarpophalangeal and metatarsophalangeal joints, 
calcaneus, sacroiliac joints and spine. Less frequently 
changes may be found in the knees, ankles, 
sternocalvicular, and costovertebral joints. The disease 
rarely affects the hip and glenohumeral joints. 
The distribution of psoriatic arthritis can vary, with 
certain distinctive characteristics. An asymmetrical or 
unilateral joint involvement is more common in psoriasis 
than rheumatoid arthritis. The upper and lower 
extremity joints are involved in psoriasis, in contrast to 
Reiter's syndrome with predominantly lower extremity 
involvement. The abnormalities in phalangeal tufts and 
calcaneus in psoriatic arthritis are characteristic. 
In the axial skeleton, the abnormalities predominantly 
affect the spine and sacroiliac joints. The symphysis 
pubis and tendinous insertions at the pelvis may also 
demonstrate abnormalities.
Radiological Abnormalities at 
Peripheral Joints
The radiological abnormalities of psoriatic arthritis 
include erosive arthropathy at the distal interphalangeal 
joints of the hands.5 The erosion starts at the periphery 
of the articulation and extends into the centre. (Fig. 1) 
Asymmetrical involvement of the interphalangeal joints 
of the hands and feet are common.  Irregular periosteal 
bony proliferation resulting in periostitis is a typical 
presentation. (Fig.2) There is also presence of ankylosis 
of the joints, with lack of osteoporosis. The resorption of 
the tufts of the distal phalanx in the hands and feet is 
characteristic for psoriatic arthritis.6 The progressive 
osteolysis may progress to destruction of most of the 
phalanx. The eroded small bones are irregular in outline.  
The expansion of the base of the distal phalanx 
combined with the middle phalanx gives "pencil and 
cup" appearance.  
High-resolution ultrasound and ultrasound together 
with power Doppler are sensitive in diagnosing 
synovitis in the case of established psoriatic  arthritis.7 
Magnetic resonance imaging (MRI) is useful in 
assessing the synovitis in cases of psoriatic arthritis. The 
MR appearance of synovitis may be indistinguishable 
from that of rheumatoid arthritis even with dynamic 
imaging techniques.8  However, the type and site of the 
lesions, as well as other typical abnormalities like 
enthesitis can help to differentiate psoriatic arthritis 
from other arthritis.9 Other forms of MRI abnormalities 
include bone marrow oedema at the subchondral and 
diaphyseal regions; the latter one is relatively specific to 
psoriatic arthropathy.9
Manifestation of Radiological Abnormalities 
in Psoriatic Arthritis
Dr. Y. WONG 
Dr. Y. WONG 
Department of Radiology, Baptist Hospital, Hong Kong
Fig.1 Distal interphalangeal 
joint in psoriatic patient 
with narrowing of joint 
space,  marginal  and 
central erosions (arrow). 
Mild flexion deformity is 
noted. 
Fig.2 Radiograph shows soft 
tissue swelling, with bony 
erosion and proliferation 
compatible with periostitis 
( a r r o w )  i n  p s o r i a t i c  
arthropathy.
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Enthesitis
One characteristic feature of psoriatic arthritis is 
inflammation of the entheses, at the attachment sites of 
tendons, ligaments, fascia and joint capsule to bones.  
The locations include the posterior and inferior surfaces 
of the calcaneus, femoral trochanters, ischial tuberosities, 
medial and lateral malleoli, ulnar olecranon, and the 
anterior surface of the patella.10 Oriente et al have found 
peripheral enthesitis in 20% of their patients with 
psoriatic arthritis with a peak value of 30% in the 
spondylitic pattern.11 In calcaneus, the bone erosion at 
the plantar aspect results in sclerosis of bone with 
irregular and poorly defined enthesophytes at the 
attachment of the plantar ligament and aponeurosis. The 
enthesophytes will be sharply delineated in outline, and 
occasionally becomes eburnated.
Recently, ultrasound has been used as a sensitive 
imaging modality to assess the enthesitis.  Lehtinen et 
al12 and Balint et al13 first described sonographic  
features in  limb enthesitis, showing a high frequency 
of asymptomatic abnormal findings. The abnormalities 
include loss of normal fibrillary echogenicity, with 
increased thickness or intralesional focal changes at 
tendon insertion.  Power Doppler can show abnormal 
hyperaemia and vascularisation in enthesitis.14 (Fig.3)   
MRI with its fat saturation sequence can demonstrate 
early enthesitis, which presents as diffuse bone marrow 
and soft tissue oedema.15 The enthesitis is characterised 
by extracapsular inflammation at the insertions of 
ligaments and tendons with bone marrow oedema at 
attachments. Enhancement of ligament and bursa after 
intravenous injection of gadolinium contrast is also 
present.  MRI is also a more sensitive imaging tool in 
assessing the treatment response in enthesitis.16 
Vertebral Abnormalities
Sundaram and Patton have described paravertebral 
ossification, which was noted in 17% of psoriasis 
patients.17  The typical paravertebral ossification around 
the lower thoracic and upper lumbar vertebrae can be 
seen as an early manifestation of the disease. The 
ossification typically presents as fluffy and curvilinear 
radiodensity on the side of the vertebrae which is 
parallel with the vertebral body and intervertebral 
discs. (Fig.4) The ossification can merge with disc 
tissues. Its location away from the vertebral coloumn 
distinguishes the lesion from syndesmophytosis of 
ankylosing spondylitis. De Vlam and Mielant believe 
that the ossification shows less involvement of the 
apophyseal joint. The normal posterior spinal mobility 
leads to greater tensile forces anteriorly and promotes 
paravertebral inflammatory and bone formation. In 
ankylosing spondylitis, the involvement of the 
apophyesal joints reduces spinal mobility and leads to 
syndesmophytes formation.18  
The cervical spine may demonstrate discovertebral 
junction and apophyseal joint erosion, as well as bone 
ankylosis and atlantoaxial subluxation.  The atlantoaxial 
subluxation changes in psoriatic arthritis may resemble 
rheumatoid arthritis.19
Sacroiliac Joint Abnormalities
The reports on the prevalence and patterns of sacroiliac 
joint abnormalities in psoriasis show lots of 
discrepancies due to patient selection, techniques of 
radiological examinations, and image interpretations. 
In plain radiographs, about 10 to 25% of patients with 
moderate to severe psoriatic skin diseases have 
sacroiliac joint abnormalities.20,21 Bilateral sacroiliitis are 
more common than unilateral involvement.22 The 
radiological abnormalities include sclerosis and 
erosions, first involving the ilial side. Joint space 
narrowing and ankylosis will happen in the late stage.  
However, the presence of ankylosis will be less than 
classical ankylosing spondylitis. Bone proliferation at 
the tendon insertion point including the iliac crests and 
ischial tuberosities is also frequently seen. 
MRI is much more sensitive in the detection of early 
sacroiliitis. The changes include bone marrow oedema, 
sacroiliac joint erosion and sclerosis. Muche and 
colleagues23 confirmed that sacroiliitis was very 
common in psoriatic arthritis as revealed by MR. They 
most often involve the dorsocaudal part of the joint in 
early disease, with subchondral bone marrow oedema a 
frequent finding. (Fig. 5)  Williamson showed that 
sacroiliitis was present in 38% of a group of patients, 
some with absence of symptoms.24 
Fig.3 Ultrasound colour Doppler shows cortical irregularity 
with increase in thickness and colour flow at Achille's tendon 
insertion in calcaneum. The findings are suggestive of active  
enthesitis (arrow). (Courtesy of Dr. L. F. Chau)  
F i g . 4  C u r v i l i n e a r  
p a r a v e r t e b r a l  b o n e  
ossification (arrow) at 
intervertebral space in upper 
lumbar level,  which is 
characteristic of psoriatic 
arthritis. There is also 
presence  of  b i lateral  
sacroiliitis with obliteration 
of the joint space and 
ankylosis, also typical for 
psoriatic  arthropathy.  
(white arrow)
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Dactylitis
Dactylitis has been defined as one of the dominant 
clinical findings in psoriatic arthritis.4,10   In the past, the 
sausage-like appearance was thought to be due to the 
presence of concomitant flexor tenosynovitis and 
arthri t is  of  the metacarpophalangeal  and 
interphalangeal joints. Olivieri and his group had 
demonstrated dactylitis in fingers and toes and showed 
the presence of tenosynovitis with effusion.25-27 The 
flexor tendons were more often involved than extensor 
tendons, with small joint synovitis uncommon (from 6% 
to 27% ). The same group also showed that 
peritendinous soft tissue oedema was causing the 
digital swelling, and bone marrow oedema was not 
seen at the entheseal insertions of the flexor and 
extensor tendons. They concluded that the dactylitis is 
due to flexor tenosynovitis and that distension of the 
joint capsule is not an indispensable condition for 
'sausage-like' feature in dactylitis. They showed that 
clinical examination is a sufficient method for 
diagnosing tenosynovitis as it showed 100% sensitivity 
and specificity compared with MRI.  
Bony proliferation with periostitis in metaphysis and 
diaphysis in the hands and feet is a late striking feature 
of psoriatic arthropathy following dactylitis.29 Periosteal 
bone formation may cause significant cloaking of the 
phalanx, metacarpal or metatarsal bones. The changes 
are likely secondary to tenosynovitis.25 
Differential Diagnosis
The radiographic abnormalities in psoriatic arthritis are 
similar to other seronegative spondyloarthropathies, 
namely ankylosing spondylitis and Reiter's syndrome. 
The Reiter's syndrome shows less frequent ankylosis 
than psoriasis and ankylosing spondylitis. The 
osteolysis in the terminal phalanx is also characteristic 
for psoriasis.
In psoriatic arthritis, there is often asymmetrical 
involvement of the upper and lower extremities with 
predilection for small joints in the hands and feet. In 
Reiter's syndrome, lower limb involvement is more 
common. For ankylosing spondylitis, axial involvement 
is more frequent.
For the spinal involvement, ankylosing spondylitis 
usually has symmetrical bilateral sacroiliitis, with 
squaring of the vertebral body and apophyseal joint 
involvement which is not frequent in psoriasis and 
Reiter's syndrome. 
Asymmetrical joint involvement, absence of 
osteoporosis, and bony proliferation are typical features 
that distinguish psoriatic arthritis from rheumatoid 
arthritis. Paravertebral ossification and sacroiliitis are 
rarely seen in rheumatoid arthritis. 
Summary
Psoriatic arthritis possesses certain radiological features 
such as asymmetrical DIP joint involvement, enthesitis, 
dactylitis and periostitis. The involvement of synovial 
and cartilaginous joints is also a common finding.  MRI 
is more sensitive in detecting early bone marrow 
oedema, bony erosion, synovitis, and sacroiliitis. 
Ultrasound can also be used in the diagnosis of early 
enthesitis and dactylitis.  Both MRI and ultrasound are 
useful imaging techniques to monitor the response in 
treatment of psoriasis. 
Fig.5 Axial T2 weighted MR study of bilateral sacroiliac 
joints in a psoriasis patient shows bone marrow oedema and 
erosion at the dorsocaudal aspect of the right sacroiliac joint. 
(arrow)  The left sacroiliac joint also shows presence of bone 
marrow oedema in the ilium.  (white arrow) The MR findings 
are characteristic of bilateral sacroiliitis. 
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Radiology Quiz
(See P.37 for answers)
What are the radiological findings?
What further investigation will you suggest to confirm the diagnosis?
Questions:
Case
M/71. 
Admitted because of shortness of breath and ankle oedema.
He had right pleural effusion and signs of congestive cardiac failure on admission. 
This chest X-Ray was taken before transfer of the patient for convalescence.
Case 1
Dr. WK TSO
Radiology Quiz 
Dr. WK TSO
Chief of Service, Department of Radiology, Queen Mary Hospital
Case 2
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Stigmata and their  Clinical  
Implications in Psoriasis:
Emotional and stress reactions to psoriasis are 
associated with physiological correlates, which in turn 
act upon organ vulnerability and debility resulting in 
flare-ups and exacerbations. In patients with psoriasis, 
stress in the form of stigmata has been indicated as a 
principal predictor of disability (Richards et al., 2001, 
Vardy et al., 2002).
Stigma and self stigma may affect the course of illness 
exacerbation and/or relative acquiescence in psoriasis. 
Fortune et al. (1997) noted that disability in psoriasis 
was best accounted for by anticipatory and maladaptive 
avoidant coping behaviour and experiences of rejection. 
Depression, common in psoriasis patients decreases the 
threshold for itch perception via increasing central 
nervous system opiate levels (Gupta, 1999). Yet, 
depression was found to have only a moderate 
correlation with symptom severity. Instead depression 
was more accurately predicted by perceived stigmata 
associated with deprivation of social touch (Gupta et al. 
1998), being female, a stronger belief in perceived 
severity of the consequences of psoriasis, and poor 
coping strategies (Fortune et al., 2002). Likewise, 
presence of distress in the form of uncontrolled and 
excessive worrying slowed clearance of psoriasis using 
a standard therapy of psoralen plus ultraviolet A 
treatment while combined standard therapy plus 
psychological management yielded superior results at 
up to 6 months follow-up (Fortune et al., 2003).
Goffman (1963) cautioned that stigma "is deeply 
discrediting", and a stigmatised person may be reduced 
"from a whole and usual person to a tainted, discounted 
one". Link, Yang, Phelan, and Collins (2004) further 
noted that labelling, stereotyping, cognitive separation, 
emotional reactions, status loss and discrimination may 
all be involved. Psoriasis may be more accurately seen 
as a recurrent medical condition as well as an adverse 
and salient social (and internal) stimulus for the 
afflicted. The adverse consequences of psoriasis include 
not only physical sufferings, but also the precarious 
management of visible regions, coping with a 
subjectively all-consuming disease, psychological co-
morbidity, and social vulnerability (Schmid-ott et al., 
2005). Multiple interpersonal concerns were reported by 
psoriasis patients. Krueger et al. (2001) provided survey 
results which indicated that 27% of the patients had 
difficulties with sexual activities, 81% were 
embarrassed with visible psoriasis, and 88% expressed 
concerns about the disease worsening. Likewise, 
Langley et al. (2005) in their review of the literature 
indicated that up to a third of patients with psoriasis 
suffered from pathological worry and anxiety which 
impinge on "all aspects" of thepatients' daily life. 
Stigmata are multi-faceted. A useful tool for measuring 
stigma is the Questionnaire on Experience with Skin 
Complaints (QES) by Ginsburg & Link (1989). Six 
dimensions of stigmata were measured including: 
An all Encompassing Clinical 
Management Approach Advocated
Psoriasis is thus more effectively managed with a 
combined medical as well as social learning perspective, 
incorporating variables such as the perceived degree of 
social rejection, suspicion and misguided fear of 
infection. Indeed, Vardy et al. (2002) provided data to 
indicate that severity of perceived stigma mediated the 
impact of severity of psoriasis on quality of life. 
Effective management and harm containment of the all-
encompassing adverse impact of psoriasis should best 
incorporate an understanding from an insider's 
perspective on "how it is like" to live with psoriasis. 
Therapeutic aims should include targeted attempts to 
reduce the challenges of psoriasis on the person's self 
image, social functioning and emotional reactions.
Illness management is more effective to the extent that 
the external signs of psoriasis detrimental to the social 
standing (stigma) and self esteem (self stigmata) could 
be reduced. The two interlinking processes are likely to 
be mutually potentiating. Perceived stigma and social 
rejection prompt fear, self depreciation, avoidance, 
Interference of skin symptoms and self-esteem: 
feelings of being worthless, alone or unclean;
Outward appearance and situation-caused retreat: 
experience of lack of physical attractiveness or 
sexual desirability, special ways of dressing, 
avoidance of public situations;
Rejection and devaluation: anticipated and 
perceived negative reactions of others;
Composure: calmness and confidence in a 
satisfactory life despite the psoriasis;
Concealment: tendencies toward hiding the 
diagnosis and keeping the disease secret;
Experienced refusal: feelings of stigmatisation in 
specific situations such as shopping or usual public 
transport. 
Overcoming the Stigmata of Psoriasis
Prof. Peter WH LEE
Prof. Peter WH LEE
Hon. Professor, Department of Psychiatry, The University of Hong Kong
Adjunct Professor, Department of Psychology, Chinese University of Hong Kong
Hon. Consultant in Clinical Psychology, Hong Kong Sanatorium & Hospital
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anxiety, uncertainty, insecurity feelings, depression and 
demoralisation. Self stigma that arises from the patients' 
own rejection of the condition as well as projection of 
rejection by others may aggravate self devaluation and 
"spread" of negativity. The phenomenon of spread has 
been well reported in the health psychology literature. 
Spread refers to rejection and devaluation of the entire 
person over and beyond the confines of the symptoms. 
Pain and itchiness aside, psoriasis diminishes a person's 
social standing and self esteem. Personal weaknesses 
may be further opened up leading to a vicious cycle of 
fixation and worry about the sight, pruritus and 
uncertain prognosis of psoriasis, anxiety and depressed 
mood, reduced quality of life, enhanced physiological 
stress reactions, negative fixation, symptom flare-ups 
and exacerbations. On the other hand, overcoming and 
accepting the sometimes unavoidable stigmata of 
psoriasis may lead to greater peace of mind, less 
emotional upheavals, and greater treatment adherence. 
Acceptance alongside realistic reduction of perceived 
stigmata reduces depressed mood and anxiety, more 
positive overall quality of life, reduced inflammations 
and exacerbations. 
The Unity of Mind and Body
The unity of mind and body and their inevitable 
interactions is very well illustrated in conditions such as 
psoriasis. Few clinicians would disagree that 
psychological or behavioural factors play a role in almost 
every medical condition, especially in conditions that are 
visible and stigmatising and those with accompanying 
adverse psychological aftermaths of low self esteem, 
depression, anxiety, avoidance, and social awkwardness. 
While the diathesis or illness susceptibility is clearly of 
genetic origin, some individuals may become more 
vulnerable and may even be designated as being skin 
reactors. Individuals with alexithymia having more 
difficulties in identifying feelings and describing feelings, 
with poor emotional regulation and excessive 
preoccupation with physical symptoms and external 
events were implicated as being at greater risk (Richards 
et al., 2005). 
On a broader consideration, today's terminology has 
discarded the term "psychosomatic illness" which 
implicated only a limited number of disease conditions 
as having a psychosomatic origin. Instead, the more 
encompassing term of "psychosomatic approach" to 
illness management is regarded as being more clinically 
realistic. The DSM diagnostic nomenclature (APA, 1994) 
further delineates the multifarious psychosomatic 
processes under the diagnostic category of 
"psychological factors affecting general medical 
condition". Specifically, psychological factors may affect 
a medical condition through exacerbating the underlying 
disorder, reducing coping effectiveness, prompting 
maladaptive behaviours, intensify stress related 
physiological responses and  lead to further outbreaks of 
the underlying disorder. In psoriasis, psycho-
behavioural-neuro-immunological factors implicating 
chronic inflammatory changes, symptom exacerbation, 
IL-22, TH-17 cells, and depression may be implicated in 
its recurrent cycle of initiation, progression, aggravation 
and relative acquiescence (Leibovici et al, 2010).  
 
Improved Awareness and Training 
Required in Detecting Psychological 
Distress
A misleading feature of psoriasis is that it does not even 
have to be visible for the patient to fear and anticipate 
social rejection, and also that it does not need to be 
objectively severe to warrant severe disability and 
distress (Ginsburg, 1995). It is thus not surprising to 
note that while most clinicians would agree that 
psychological factors may affect the course and 
management of psoriasis, they are also poor in 
detecting psychological distress in their patients. A low 
consensus between the respective patients' and their 
physicians' reports of presence of severe psychological 
distress was noted (Richards et al., 2004). Indeed 
regardless of the doctor's empathy level, severe 
psychological distress in 61% of their patients was not 
identified. Even when severe anxiety and depressive 
reactions were noted, in the majority of cases, no further 
action was taken following the consultation. Sampogna 
et al. (2003) also provided disappointing data to 
indicate that dermatologists did not have an accurate 
perception of the extent of psychiatric disturbances in 
their patients with skin conditions. 
Richards et al. (2004) thus asserted that "It is of key 
importance that psychological distress is appropriately 
recognised and addressed in a holistic or 
biopsychosocial approach to patient management". 
They thus advocated the use of specific guidelines and 
education in psychological detection skills as well as 
routine administration of psychometric screening tools 
such as the HADS.
Janowski and Pietrzak (2008) provided helpful 
indications to guide clinicians in referring psoriasis 
patients for psychological interventions including:
C o n c l u d i n g  R e m a r k s  a n d  
Recommendations
Instead of a cross-sectional approach where symptoms 
are managed as and when they arise, a longitudinal 
approach to psoriasis with understanding of the 
individual patient's vulnerability, high stress points, 
Presence of psychiatric and behavioural disorders 
(depression and anxiety disorders, suicidal 
ideation) as co-morbidity with psoriasis;
History indicating psychological stress as a 
psoriasis-triggering or aggravating factor;
Significantly decreased quality of life, where social 
relationships, sexual functioning and self-esteem 
are seriously affected;
Increased pruritus; 
Increased feelings of stigmatisation as indicated by 
sensitised attention to potential rejecting behaviours 
of others, biased interpretation of others' 
behaviours and intentions, or anticipatory 
expectations of unfavourable reactions from others;
Psoriasis being unresponsive to standard 
pharmacological treatments;
Children and adolescents with psoriasis (given 
psoriasis being an increased risk for disturbances of 
normal psychosocial development).
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sense of stigmata, and factors associated with 
exacerbation is advocated. The aim is to equip the 
patient with awareness of aggravating and stress factors 
inherent in themselves and in their life circumstances, 
and learn to short-circuit stress responses and 
aggravations at the earliest stage. Self monitoring of 
illness aggravating correlates in the form of life events, 
behavioural and emotional responses are useful. For 
example, psychological variables may maintain and 
exacerbate psoriasis by eliciting poor compliance and 
scratching behaviours. A general attitude of negative 
affectivity may prompt more helpless and depressive 
responses, rendering adherence to treatment unreliable 
(Charman and Horne, 1997). 
A systems approach to managing psoriasis is also 
proposed. The clinician needs to recognise that psoriasis 
is at the same time a lifelong medical illness as well as 
an illness with vast social and personal implications. 
Understanding the patient's perceptions regarding the 
illness, his/her unique life circumstances, as well as 
reactions to psoriasis facilitates better physician-patient 
communication, trust and collaboration.
Effective management of negative emotions needs to 
be built into the overall management plan. Anger, 
depression and anxiety are common emotional 
conditions of maladjustment. Anger leads to non-
adherence, emotional instability, and increased 
scratching behaviours. Depressed mood leads to and 
may be aggravated by social avoidance, low self-
esteem, sense of helplessness and hopelessness. 
Anxiety leads to dread, insecurity and uncertainty 
feelings, inhibition, and reduction in meaning and 
gratification in daily living. All in all, vulnerability is 
accentuated by chronic negative emotions, leading to 
unsatisfactory illness control and management. The 
cognitive behavioural approach to management of 
emotions postulates that extreme, distorted and over-
inclusive thoughts underlie negative emotions. 
Understanding and managing the patient 's  
conceptions about his/her illness and associating 
coping styles facilitates emotional management and a 
less stormy illness course (Fortune et al., 2002, 2004; 
Zachariae et al. 1996). 
Specific interventions have also been indicated to be 
useful. For example, behavioural methods for habit 
reversal in reducing scratching had been indicated as 
being useful. Illness control was demonstrated to 
improve significantly with targeted psychological 
therapies (autogenic training, relaxation, self control, 
stress management, and management of illness 
attribution) compared with interventions consisting 
only of information giving and psychoeducation 
(Ehlers et al., 1995). 
Psychological screening and interventions clearly hold 
the promise for being a useful adjunctive treatment in 
the overall management of psoriasis. 
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Introduction
Psoriatic arthritis (PsA) is a disease with diverse 
manifestations. Oligoarthritis is a common pattern 
identified; however, it could take the form of 
rheumatoid-like disease or inflammatory spondylitis. 
Distal interphalangeal joint involvement and arthritis 
mutilans are distinctive features of PsA. Enthesitis and 
dactylitis should also be aware of. It is important to 
recognise the different forms of presentation and to 
realise that therapeutic options are not equally effective 
across different patterns of PsA. 
Moreover, traditional disease modifying anti-rheumatic 
drugs (DMARDs) have limitations and more effective 
agents are very much needed. With the advances in the 
understanding of immunological disturbances in 
inflammatory arthritis and the success of using anti-TNF 
in the management of rheumatoid arthritis, investigators 
have identified biologic agents that have filled at least to 
some extent the gaps in the treatment of PsA.
Different anti-TNF agents have been reported to be 
efficacious in treating PsA, which was also supported 
by systemic reviews and meta-analyses of the data 
available in the literature1-4. Therefore, various anti-TNF 
agents have been approved in different national 
regulatory agencies for their indication in PsA. Other 
non anti-TNF agents have been tested and would be 
discussed accordingly. 
Anti-TNF in the Management of 
Psoriatic Arthritis (Table 1)
Etanercept
A soluble TNF receptor-FC fusion protein, etanercept, 
was shown to be effective in a relatively small (No. of 
subject = 60) double blind placebo-controlled study in 
improving clinical signs (PsARC, ACR20 etc) and 
inflammatory markers (ESR and CRP)5. The efficacy in 
using 25mg twice weekly etanercept was reconfirmed by 
a larger scale consisting over 200 patients with PsA6. 
Radiological progression was also shown to be inhibited 
by the active treatment group in this large scale trial.
Infliximab
In an open label study of infliximab treatment for PsA, 
it had significant reduction of inflammation as detected 
by MRI7. This chimeric monoclonal anti-TNF antibody 
administrated by intravenous infusion was tested in the 
IMPACT and IMPACT28,9. Signs and symptoms were 
shown to be significantly improved in the active 
treatment group as compared to the placebo. Both the 
sustainability of its results and the inhibition of 
radiological progression were further demonstrated in 
the 2-year extension of IMPACT study10.
Adalimumab
Adalimumab is a humanised monoclonal anti-TNF 
antibody given by subcutaneous injection on every 
other week. It has been tested in a pivotal trial, ADEPT, 
which is a 24-week randomised double-blind, parallel 
group, placebo-controlled trial. It demonstrated 
significant improvement in joint and skin 
manifestations11. Modified total Sharp score of 
radiographic structural damage was inhibited at week 
24 in the adalimumab arm. Another study conducted in 
PsA patients who failed DMARDs showed that addition 
of adalimumab (vs placebo) resulted in improvement in 
disease control12.
Golimumab
Golimumab is an humanised monoclonal antibody 
against TNF-   , which is administrated subcutaneously 
on a monthly basis. Efficacy and safety in using 
golimumab for the treatment of PsA has been 
demonstrated in GO-REVEAL, a 24-week randomised 
placebo controlled trial13. Patients with active treatment 
(golimumab 50mg or 100mg) had significantly higher 
proportions in achieving ACR20, ACR50 and ACR70. 
The beneficial effects on skin involvement, nail disease 
and enthesitis were also documented in this trial.
Biologic Therapies for Psoriatic Arthritis
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Table 1. 
Agent
Etanercept
Infliximab
Adalimumab
Golimumab
Mease 
2000
Mease 
2004
Antoni
2005
Antoni
2005
Mease
2005
Genovese
2007
Kavanaugh 
2009
Outcome
PsARC, ACR 
20/50
ACR 20, 
PsARC, HAQ-DI
ACR 20/50/70, 
PsARC, HAQ-DI
ACR 20/50/70, 
PsARC, HAQ-
DI, PASI 
50/70/90, SF-36
ACR20/50/70, 
TSS, PsARC, 
PASI50/70/90, 
HAQ-DI, SF-36
ACR20/50/70, 
TSS, PsARC, 
HAQ-DI, SF-36
ACR20/50/70, 
PASI50/70/90, 
HAQ-DI, SF-36, 
NAPSI, MASES
Trial
IMPACT
IMPACT 2
ADEPT
GO-REVEAL
No.
Active/control
30/30
101/104
52/52
100/100
151/162
51/49
292/113
Duration
(weeks)
12
24
16
16
24
24
24
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Biologic Therapies Other than Anti-TNF
Alefacept
An approved agent for the treatment of plaque psoriasis, 
Alefacept, is a fusion protein of the first extracellular 
domains of human lymphocyte function-associated 
antigen 3 (LFA-3) and Fc portion of IgG1. Alefacept 
inhibits T cell activation by blocking co-stimulation CD2-
LFA-3. It was tested in a setting of weekly intramuscular 
injection for 12 weeks in combination of methotrexate14. 
However, statistically significant different improvement 
was only achieved in ACR 20 but not ACR 50 or ACR 70. 
An open-label extension was also reported recently15. 
Nevertheless, it has not been accepted as one of the 
options used in the treatment of PsA.
Ustekinumab
An inhibitor of interleukin 12/23, ustekinumab binds to 
the P40 subunit of these two interleukins preventing 
their binding to the 12R  1 receptor on the surface of T 
cell, NK cells and antigen presenting cells. It has already 
been approved for the management of plaque psoriasis. 
A crossover trial was conducted in 146 PsA subjects, 
which showed promising results in terms of its efficacy 
in improving the manifestations of joint inflammation, 
skin disease, enthesopathy and dactylitis16. A larger 
scale study is needed to confirm its usefulness in the  
management of PsA.
C l i n i c a l  G u i d e l i n e s  a n d  
Recommendations
Guidance in using anti-TNF in PsA has been published 
by professional societies, like the British Society for 
Rheumatology (BSR)17. Patients with pure axial 
disease are suggested to adopt the guidance similar for 
patients with ankylosing spondylitis. Patients with 
peripheral arthritis who continue to have persistent 
active disease (defined as > 3 SJC and > 3 TJC on 2 
separate occasions 1 month apart) despite an adequate 
trial of 2 standard DMARDs individually or in 
combinat ion (sulphasalazine,  methotrexate ,  
cyclosporin or leflunomide) should be considered for 
the use of anti-TNF. Apart from the above key 
principles, the guidance also provides details on the 
definition of an adequate trial of DMARDs, exclusion 
criteria, criteria for withdrawal of therapy and 
assessment during anti-TNF therapy.
More recently treatment recommendations for PsA 
have been developed by an international organisation, 
namely, the Group for Research and Assessment of 
Psoriasis and Psoriatic Arthritis (GRAPPA)18. The 
recommendations have a comprehensive coverage of 
clinical manifestations of PsA including peripheral 
arthritis, skin and nail diseases, axial disease, dactylitis 
and enthesitis. It is apparent that the use of biologics 
in particularly anti-TNF is recommended in patients 
with moderate to severe degree of all these 
manifestations (Table 2).
Despite of all these enthusiasms, one should remember 
the potential adverse effects that may happen with the 
use of anti-TNF. Infections, in particularly 
tuberculosis(TB), are known complications. Proper TB  
screening has been proved to significantly lower the 
risk of developing TB during the course of anti-TNF 
therapies. Clinical assessment of cardiac function and 
the possibility of having an underlying malignancy or 
an autoimmune disorder such as lupus should all be 
carried out. Pre-treatment serologic testing for hepatitis 
B and C status are also required.
Conclusion
The treatment of PsA has significantly changed by the 
development of biologic therapies. Clinicians should all 
be aware of the erosive and progressive nature of PsA. 
All patients with moderate to severe disease should not 
be denied of the chance for a better control of their 
disease by using biologic therapies if clinically 
appropriate. Therefore, early detection, early treatment 
and timely referral to specialists could not be over-
emphasised.
Table 2
Systemic Rx
NSAID
DMARDs
Biologics
Peripheral arthritis
 
SSZ, MTX, CycA, LEF
Anti-TNF
Skin and nail disease
x
MTX, CycA
Anti-TNF, Alefacept
Axial disease
 
x
Anti-TNF
Dactylitis
 
?
Anti-TNF
Enthesitis
 
       ?
Anti-TNF
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Asked to write about leisure activities for the medical 
community, I immediately thought of Travels. I have 
two kinds of travels in mind: one spatial and the other 
mental. I cannot do without either of them, especially 
the latter kind!
Being raised in a rather closeted environment (my 
parents would not even consider sending me to live in a 
hostel for my university studies), my first travel outside 
Hong Kong had to wait till I graduated from my 
medical studies in 1970! And it was - you would hardly 
believe this - to Macau for one night! Which is the 
reason why I planned and saved and super-planned for 
a one week 'flying' visit to Rome, Florence and Venice, 
at the very first opportunity I could grab, and this was 
only after completing my first year as a registrar at the 
University Department of Medicine, in July 1972. In 
those days interns did not have a single day of leave 
throughout their internship; I had to wait till I had been 
a registrar for a full year before I was allowed a one 
week holiday. And even that one week hard-earned 
holiday was 'unofficial'. As a result though my ward 
physician gave me his full blessing before I took my 
first real travel abroad, I was terrified when I was one 
full day late for returning to work due to a flight delay 
from Venice to Rome! My colleagues all warned me on 
my return that Professor David Todd, who was then the 
virtual head of the Department, was very angry about 
my escape abroad! Well, I survived Professor Todd's 
anger, but only just!
Since then I have become famous in my Department for 
my annual, and often more frequent than annual, 
travels abroad. For how can one not pine to visit all the 
beautiful, and often more than beautiful, places on our 
wonderful planet! The aquamarine depths of the oceans 
surrounding the Thai islands, the ever-changing colours 
of the lakes of Jiuzhaigou, the innumerable shades of 
reds and oranges of the autumn maple leaves in Japan 
(which are smaller and more delicate than maple leaves 
elsewhere), the awesome chasm of the Grand Canyon, 
the wonderful chaos of the Times Square, the  Georgian 
and Victorian buildings of  London which seemed to 
me such old friends even on my very first visit in 1974, 
the majesty and symmetry of Haussmann's plan for 
Paris, the ancient architecture of old Rome where each 
cobblestone one treads might have been touched by 
Julius Caesar or Cicero, the mystic centre of Jerusalem 
so heavily and tragically laden with religious fervour 
(Muslim Dome of the Rock, Christian Via Dolorosa, and 
Hebrew Wailing Wall), and, back to nature, the deep 
dark glory of Homer's wine-red Aegean Sea... My list of 
just ten places is less than adequate to express my 
yearning to experience the natural and man-made 
wonders of the world! I have not mentioned the 
compressed complexities of the South Island landscape 
of New Zealand, the seething restless surface of the 
Yellowstone Park nor the bluer-than-blue Tuscan sky! 
But how can I even attempt to do justice to the infinite 
variety of the earth by just a few hundred words!
Maybe you have been wondering why I chose to visit 
Italy on my first sneak 'flying' visit. The answer is very 
simple. Well before I could travel abroad without 
depending on my parents' permission and fund, I had 
been travelling mentally for over one decade, by 
reading any books I chose to read! I was saturated with 
Michelangelo and his Vatican frescos and his sculptures 
scattered over Rome and Florence before my escapade 
in 1972. What freedom one could/can achieve just by 
sitting in a chair. I could read novels and histories and 
art-books right under my mother's watchful eyes 
without her suspecting that I was not diligently 
studying my school textbooks. And try to figure out the 
miracle of tracking the innermost workings (and 
foibles) of the mind of any genius just by looking at the 
written words printed on a page! I love books probably 
more than even travelling. My love for books, i.e, non-
medical books of almost any variety, is so great that I 
find it difficult to walk by a bookshop without entering 
for a good browse, in case any new good books have 
arrived in the last few days! My love for books extends 
to the smell and the feel of the pages of a paperback. I 
recently read that Philip Roth, the American novelist 
who surely should be awarded a Nobel Prize, predicts 
that computer comics, digital wares and blockbuster 
films will soon replace the public appetite for books, 
good old books with pages to turn over with your own 
fingers. I sincerely hope this is not going to be true!   
One of my favourite motto to medical students is 'No 
knowledge is useless'. By this I do not just mean a 
broad-based medical knowledge; I include all we can 
possibly learn from the wisdom and insights of other 
people's superior mental faculties. In my early teens, I 
learned to love the gymnastics of the English language 
from Charles Dickens; I learned to look at the murky 
intricacies of the human mind from Iris Murdoch and 
Feodor Dostoyevsky; I learned about wild passions 
from Emily Bronte. In the ensuing five decades [you 
already know my (old) age from my year of 
graduation!], I learned more, much more, from my 
mental odyssey with such diverse authors (in 
alphabetical order) as: Saul Bellow and his massive 
epics of American struggles, Boccaccio and his 
pornographic 'Decameron', Joseph Conrad and his 
Travels
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mindscape of darkness, Charles Darwin and his 
revolutionary evolution findings (albeit written in 
clotted prose), George Eliot and her more-than-
masculine intellect, TS Eliot and his elegant, difficult 
verse lines,  Flaubert and his meticulous human 
depiction, Thomas Hardy and his sardonic universe, 
Hermann Hesse and his strange journeys into the mind, 
Marcel Proust and his wordy meanderings that sparkle 
with new insights, and Sophocles and his astonishing 
detective drama of Oedipex who kills his father and 
marries his mother unknowingly (the origin of Freud's
Oedipex complex)... And of course towering above 
them all, there is the all encompassing illimitable 
intellect of William Shakespeare, whom I first 
approached with much trepidation, only to be 
overwhelmed by his tremendous human insights, 
verbal dexterity and poetic profundities. (Incidentally I 
still approach Shakespeare with some trepidation!)
But once again, how can I do justice to the mental 
travelling through books by just a few hundred words. 
The rest, as Shakespeare says, is silence... 
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1. Running along the Island East Corridor at dawn
2. The infamous Bah-Kut-Teh
Serendipity was what started William running. We 
were living in East London at the time. The route of the 
London Marathon partly traverses the wind tunnels 
that meander between the towering heights of Canary 
Wharf. I hadn't realised how serious this running 
business was then. One evening, the runner returned 
with an ankle the size of a football, the colour of 
blueberries and feel of Jell-O. He'd continue running 
despite having jammed the ankle in a pothole off East 
India Road. He was off training for 6 weeks.
When we moved to Hong Kong, I had imagined that I 
would just be a bystander. Not so. I sat in Victoria Park 
for a considerable time one morning, awaiting his 
return during the last Standard Chartered Hong Kong 
Marathon. I was waiting at the wrong spot. 
But it was pleasant to witness the startling change of 
night sky into a lovely shade of pink as the sun appeared, 
and hear the merry chirp of birds, fresh from their sleep. 
The Sunday regulars (a group of old-aged pensioners) 
were not so happy, however, to have me camp on the 
bench where they meet to socialise. I soon got the 
message and moved off to more welcoming pastures!
It was so much more interesting when William decided 
to chase the marathons across Asia. At last, I could be a 
tourist. First stop was Kuala Lumpur, Malaysia. It was 
hot and humid, but the shopping was satisfying. Satay, 
laksa and durian were a bonus. The marathon route 
was mainly composed of a series of seemingly 
interminable highways. But a group of mothers with 
their strollers along the 10km route was a surprising 
and heartwarming sight.
The Borneo Marathon is held in Kota Kinabalu 
annually. This is where you will find the tallest 
mountain in Southeast Asia, Mount Kinabalu. The run 
takes you through the local fish market and the newly 
built Likas Stadium. The smell of the morning's catch is 
as breathtaking as the wide open sea views. One also 
gets to enjoy the obligatory carbohydrate-loading pasta 
party the evening before. 
In Singapore, the queues for runners' packs were 
perfectly formed and participants behaved in an orderly 
fashion. The event started at 5:30 a.m. I was snuggled 
up comfortably in the hotel until it was time to venture 
out to Rangoon Road. Any tourist to the Lion City must 
eat at Ng Ah Soi's Bah-Kut-Teh joint. This is reportedly 
the place that turned down our Chief Executive, Mr 
Tsang's request for a bowl of fragrant soup. That aside, 
they furnish you with your own stove to keep the kettle 
boiling and tea flowing. The aroma of the herbs was 
strangely refreshing and the ribs tender yet meaty. 
There was torrential rainfall and we were trapped but 
completely happy and satiated.
The Grand Palace in Bangkok is an amazing starting 
and finishing point. They have been organising the 
Standard Chartered Marathon here for 20 years. The 
full marathon started at an ungodly hour of 2 a.m. 
Crossing the two bridges across the Chao Phraya River 
was, I am told, an awesome experience. I can't say much 
for the terrifying ride in the river taxi though. The river 
was busy and the taxi was packed to the hilt with locals 
and tourists, no safety equipment in sight. One caution 
for runners though. Do avoid the lovely spicy food 
before the run. It makes runner's diarrhoea so much 
more prolific and unpredictable! 
Running Asia - Chronicles of a Runner's Wife 
Dr. Siaw Ing YEO
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Frankly, I don't mind this running malarkey. It takes me 
places I've never been before and I get to savour 
firsthand the local customs and fare. Also there are 
hundreds of photos which I can share with friends on 
Facebook.
It's really painless too. I'm not the runner with the stiff 
muscles, refractory plantar fasciitis, aching ilio-tibial 
band or the upset stomach. In fact, I'm rather looking 
forward to accompanying the marathon runner in 2010. 
New York, Boston, Sydney, Berlin, anyone?
 
3. The Grand Palace, Bangkok
Federation News
    32
VOL.15  NO.5  MAY  2010
On Friday, 19 March 2010, the Federation was honoured to have invited Dr. HK 
MONG, Chairman of the Institute of Advanced Motorists Hong Kong and Mr. 
Stephen HUNG, Chairman of the Criminal Law and Procedure Committee of the 
Law Society of Hong Kong to deliver a talk on Safe, Smart & Advanced Driving 
and Non-compliance & Consequences.  The talk was well attended by medical 
professionals and lawyers. The two speakers shared their precious experience 
with the participants on the topics and addressed their hot questions.  
The talk finished with a lucky draw in which Lexus sponsored a pair of 
gentlemen and ladies watches, and National Australia Bank sponsored an iPod 
and 4 concert tickets.  The Federation was also thankful to Lexus and National 
Australia Bank's sponsorship for a delicious refreshment at the event and 
souvenirs for the speakers and participants.  Everyone had a fruitful evening 
with information attained from the talk and souvenirs from our sponsors.
We are delighted to announce that a Test Drive will be held in July to put the 
theories into practice.
Dr. HK MONG 
talking on the 
topic of Safe, 
Smart & 
Advanced 
Driving
The speakers at 
Q & A
Mr. Stephen 
HUNG talking 
on the topic of 
Non-compliance 
& Consequences
The speakers and 
the Federation 
President, Dr. 
Raymond LO
 
Winners of the 
Lucky Draw
Driving Talk
Venue or Meeting
Facilities
Member Society
(Hourly Rate HK$)
Peak
Hour
Non-Peak
Hour
All day 
Sats, Suns & 
Public Holidays 
Rental Fees of Meeting Room and Facilities 
at The Federation of Medical Societies of Hong Kong
Non-Member Society
(Hourly Rate HK$)
Multifunction Room I 
(Max 15 persons)
Council Chamber 
(Max 20 persons)
Lecture Hall 
(Max 100 persons)
150.00
240.00
300.00
105.00
168.00
210.00
225.00
360.00
450.00
250.00
400.00
500.00
175.00
280.00
350.00
375.00
600.00
750.00
Peak
Hour
Non-Peak
Hour
All day 
Sats, Suns & 
Public Holidays 
(Effective from October 2009)
Non-Peak Hour: 9.30 am - 5.30 pm
Peak Hour: 5.30pm - 10.30pm
LCD Projector 
Microphone System 
500.00 per session
50.00 per hour, minimum 2 hours
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News from Member Societies
Word from the President
The Hong Kong Society of Gastroenterology
Updated office-bearers for the year 2010-2011 are as follows: President: Prof. Benjamin WONG; Honorary 
Secretary: Dr. Judy Wai-chu HO; Honorary Treasurer: Dr. Wai-cheung LAO
The FMSHK would like to send its congratulations to the new office-bearers and look forward to working 
together with the societies.   
The Federation is dedicated towards enhancing the sharing and exchange between our member societies and 
health professionals.  We shall be inviting our member societies to introduce their work and mission in our 
coming issues of the Medical Diary. The first society to introduce their profile in our Diary this year is our newly 
joined student member -- the Chinese University Medical Society. The young generation is the pillar of our 
profession in future. We shall continue to actively engage our new and existing members in Federation activities 
for professionals and the public.  
On behalf of the Medical Society, the Chinese 
University of Hong Kong, I would like to express 
our pleasure in joining the FMSHK.
The Medical Society is a non-profitable student 
association founded in 1982. It is organised by a 
group of aspiring medical students, which serve 
about 700 members in the Faculty of Medicine.
Each year, we organise a wide range of events 
from academic, recreational to social.  A charity 
event, the Medical Students' Festival, aims to raise 
fund for a beneficiary through holding different 
activities including a variety-show and a high table 
dinner among medical students. Different community health-check services are also coordinated in estate 
and different health-care centres throughout the year. Health Exhibition is an annual event, which aims at 
arousing the public's interest towards the importance of health. To extend our mission beyond Hong Kong, 
we also organise an international service trip and this year, we are heading to Vietnam to help the "Agent 
Orange" victims.  All in all, our aim is to blend the doctors-in-training with community so that medical and 
health education can be directed to the public.
Joining the FMSHK, which is the umbrella organisation of medical associations, is not only a gain in 
connections with other medical professionals but also a chance for us to further extend our community 
service towards the public in a more organised way and a larger network. We hope that our interaction with 
FMSHK and other society members will yield a healthier Hong Kong. 
Mr. Ashley Tsz-wai TSANG 
President 
Medical Society 
The Chinese University of Hong Kong
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TUE
Ms. Paulina TANG
Tel: 2527 8898 
Fax: 2865 0345
7:30 pm - 8:30 pm4 FMSHK Officers' MeetingOrganiser: The Federation of Medical Societies of Hong Kong,   Venue: Gallop, 2/F., Hong Kong Jockey Club Club House, Shan Kwong Road, Happy Valley, Hong Kong 
THU
Ms. Jaclyn LEE / Ms. Carrie 
CHEUNG
Tel: 2877 1106
1.5 CME Points for Participant 
3 CME Points for Speaker
 
1:00 pm 
8:00 pm 
6 HKMA Hong Kong East Community Network - Certificate Course: Practical Psychiatry for the General Practitioners (Session 7) Organiser: HKMA Hong Kong East Community Network, Hong Kong Society of 
Biological Psychiatry and Lundbeck Institute Hong Kong, Chairman: Dr. SHUM Ping 
Siu, Speakers: Various, Venue: Regus Conference Centre, 35/F., Central Plaza, 18 
Harbour Road, Wanchai, Hong Kong
Ms. Christine WONG
Tel: 2527 8285
HKMA Council Meeting
Organiser: The Hong Kong Medical Association, Chairman: Dr. HH TSE, Venue: HKMA 
Head Office, 5/F., Duke of Windsor Social Service Building, 15 Hennessy Road, 
Wanchai, Hong Kong
Ms. Dora HO
Tel: 2527 8285
8:00 pm 3rd Singing Course
Organiser: The Hong Kong Medical Association, Venue: ?????????
TUE
Miss Carman WONG
Tel: 2527 8285
1:00 pm 11 HKMA Kowloon West Community Network - Vaccination Organiser: HKMA Kowloon West Community Network, Venue: Crystal Room I-III, 30/F, Panda Hotel, 3 Tsuen Wah Street, Tsuen Wan, NT
ROC 2010 Conference Secretariat, c/o 
International Conference 
Consultants, Ltd., 
Tel: (852) 2559 9973
Fax: (852) 2547 9528
Email: roc2010@icc.com.hk, Websites: 
www.oshk.org.hk / 
www.hkgerisoc.org 
13 11th Regional Osteoporosis Conference - ISCD Bone Densitometry Courses and Certification Examinations 2010 & 1st ISCD Vertebral Fracture Assessment Course in Hong Kong
Venue: Novotel Century Hotel Hong Kong  and  Hong Kong Convention & Exhibition 
Centre 
MON
Dr. HUNG Hing Hoi / 
Ms. Tammy HUNG 
Tel: 2958 6006 / 9609 6064
Fax: 2958 6076 / 8344 5115
1 CME Point for College of Surgeons 
of Hong Kong 
7:30 pm - 8:30 pm
(10, 17, 24, 31)
(11, 18, 25)
8:00 pm 
3 Patients with Severe Loin Pain and Septic Shock Organiser: Hong Kong Urological Association, Chairman: Dr. FU Kam Fung Kenneth, Speaker: Dr. YEUNG Hip Wo Victor, Venue: Seminar Room, G/F, Block A, Queen 
Elizabeth Hospital, Kowloon
WED
Miss Carman WONG
Tel: 2527 8285
1.5 CME Points
1:00 pm 5 HKMA - Wuhan Project "Practical Health Informatics Course for Doctors" (Session IV)Organiser: The Hong Kong Medical Association, Mr. Edmund TSE; Mr. Michael CHIU & Mr. Clifford TSE, Venue: The HKMA Dr. Li Shu Pui Professional Education Centre, 
2/F, Chinese Club Building, 21-22 Connaught Road Central, Hong Kong
FRI
Department of Surgery, Hong 
Kong Sanatorium & Hospital
Tel: 2835 8698
Fax: 2892 7511
1 CME Point (Active)
8:00 am - 9:00 am 7 Joint Surgical Symposium - To Cover the Uncovered in Plastic and Reconstructive SurgeryOrganiser: Department of Surgery, The University of Hong Kong & Hong Kong 
Sanatorium & Hospital, Chairman: Prof. William WEI, Speakers: Dr. CHUNG Hon-Ping, 
Dr. LIU Hin-Lun, Venue: Hong Kong Sanatorium & Hospital
Miss Alice TANG /
Miss Carman WONG
Tel: 2527 8285
1 CME Point for Participant
2 CME Points for Speaker
HKMA Kowloon East Community Network - Clinical Update Series on BPH and 
Diabetes Management: Optimizing Glycemic Control for T2DM
Organiser: HKMA Kowloon East Community Network, Speaker: Dr. CHAN Wing Bun, 
Venue: Kwun Tong
Miss Viviane LAM
Tel: 2527 8452
2.5 CME Points for Participant
4 CME Points for Speaker 
MPS - Mastering Your Risk
Organiser: The Hong Kong Medical Association, Speakers: Dr. CHEUNG Kit Ying Andy 
& Dr. Justin CHENG, Venue: Mongkok or The HKMA Dr. Li Shu Pui Professional 
Education Centre, 2/F, Chinese Club Building, 21-22 Connaught Road Central, Hong 
Kong
Ms. Kitty LEE
Tel: 2814 5100
1:00 pm HKMA Yau Tsim Mong Community Network - The Impact of Post-prandial 
Hyperglycaemia in Diabetes and Cardiovascular Disease
Organiser: HKMA Yau Tsim Mong Community Network, Speaker: Dr. CHAN Wing 
Bun, Venue: Shan Tung Room 2, 8/F., Langham Hotel, Mong Kok, Kowloon 
Miss Viviane LAM
Tel: 2527 8452
2.5 CME Points for Participant
4 CME Points for Speaker
MPS - Mastering Adverse Outcomes
Organiser: The Hong Kong Medical Association, Speakers: Dr. Justin CHENG & Dr. 
CHEUNG Kit Ying Andy, Venue: Mongkok or The HKMA Dr. Li Shu Pui Professional 
Education Centre, 2/F, Chinese Club Building, 21-22 Connaught Road Central, Hong 
Kong
Ms. Candy YUEN
Tel: 2527 8285
HKMA Choir Rehearsal
Organiser: The Hong Kong Medical Association, Venue: Rehearsal Hall, Sheung Wan 
Civic Centre
Date  / Time Function Enquiry / Remarks
Dr. Y.C. PO
Tel: 2990 3788   Fax: 2990 3789
2 CME Points for College of 
Surgeons of Hong Kong 
7:30 am 12
Hong Kong Neurosurgical Society Monthly Academic Meeting Special Lecture - 
Central Nervous System Infections - A Microbiogical Perspective 
Organiser: HK Neurosurgical Society, Speaker: Dr. Samson S.Y. WONG, Venue: 
Seminar Room, G/F, Block A, Queen Elizabeth Hospital, Kowloon 
Miss Alice TANG / Miss Carman 
WONG
Tel: 2527 8285
1:00 pm HKMA Central, Western & Southern Community Network -"Certificate Course 
Management of Common Urological Problems for Primary Healthcare Providers" (II) 
Organiser: HKMA Central, Western & Southern Community Network, Chairman: Dr. 
LAM Ming Yuen, Speaker: Dr. WONG Bok Wai Byron, Venue: The HKMA Dr. Li Shu 
Pui Professional Education Centre, 2/F, Chinese Club Building, 21-22 Connaught Road 
Central, Hong Kong
(9, 29)
(13)
SAT
Ms. Dora HO
Tel: 2527 8285
4:00 pm 8 3rd Table-Tennis Training CourseOrganiser: The Hong Kong Medical Association(15, 22, 29)
Ms. Gary WONG
Tel:  3513 4821
1:30 pm 15
HKMA Kowloon East Community Network - Joint CME Course for Health Personnel 
2010 on "Perinatal Psychiatry"
Organiser: HKMA Kowloon East Community Network; Hong Kong College of Family 
Physicans & United Christian Hospital, Chairman: Dr. AU Ka Kui Gary, Speaker: Dr. 
May MIAO, Venue: Lecture Theatre, G/F, Block F, United Christian Hospital, Kowloon 
(14, 15, 16)
2:30 pm 
(13, 15, 16, 
19, 23, 25, 30)
1:00 pm 
WED
THU
SAT
Calendar of Events
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Meetings
Annual Scientific Meeting 2010 
Organiser: Hong Kong Society of Dermatology and Venerology, Enquiry: Ms. Chloe WONG, Tel: 2155 8557 / 2116 4348, Fax: 
2559 6910, Email: meeting.hk@asia.cmpmedica.com 
Hong Kong Surgical Forum - Summer 2010 
Organisers: Department of Surgery, The University of Hong Kong, Queen Mary  Hospital & Hong Kong Chapter of American 
College of Surgeons, Venue: Underground Lecture Theatre, New Clinical Building, Queen Mary Hospital, Pokfulam, Hong 
Kong, Enquiry: Forum Secretary, Hong Kong Surgical Forum, Tel: 2255 4885 / 2255 4886, Fax: 2819 3416, E-mail: hksf@hku.hk, 
Web-site: http://www3.hku.hk/surgery/forum.php
20/6/2010
10/7/2010
SUN
Miss Viviane LAM
Tel: 2527 8452
3 CME Points for Participant and 
Speaker  
2:00 pm 
2:00 pm 
16 HKMA Certificate Course on Family Medicine 2010Organiser: The Hong Kong Medical Association, Speakers: Dr. CHEUNG Kit Ying Andy & Dr. MAK Ki Yan, Venue: Queen Elizabeth Hospital, Kowloon 
SUN
Ms. Vanessa WONG
Tel: 2871 8871   Fax: 2785 1850 
3 CME points Category A (Hong 
Kong College of Paediatricians)
23 2010 Paediatric Update No.1 Common Childhood Sleep Disorders - an Update for Practising PaediatriciansOrganiser: Hong Kong College of Paediatricians, Speakers: Dr. Daniel KK NG &  Dr. 
June Sin Hang CHAN and Prof. Yun Kwok WING, Venue: Hospital Authority Head 
Office Lecture Theatre 
THU
Miss Alice TANG
Tel: 2527 828527 HKMA New Territories West Community Network - Pain ManagementOrganiser: HKMA New Territories West Community Network, Chairman: Dr. YAN Kam Sun Charlie, Venue: Plentiful Delight Banquet (????????), 1/F, Ho Shun 
Tai Building, 10 Sai Ching Street, Yuen Long, New Territories
Dr. James C.M. HO / Dr. Johnny 
W.M. CHAN 
Tel: 2255 4999    Fax: 2872 5828 
Unusual Suspect & The Prince and the Beggar
Organiser: Hong Kong Thoracic Society / ACCP(HK & Macau Chapter), Chairpersons: 
Dr. LO Ho Yin & Dr. LAU Kam Shing, Speakers: Dr. TONG Chun Wai & Dr. Raymond 
TSO, Venue: LG1, Lecture Room, Ruttonjee Hospital, Hong Kong 
Ms. Dora HO
Tel: 2527 8285
HKMA Squash Tournament
Organiser: The Hong Kong Medical Association, Venue: Kowloon Cricket Club
SAT
Ms. Clara TSANG
Tel: 2354 2440
2 CME Points for Participant
4 CME Points for Speaker 
2:30 pm 15 Refresher Course for Health Care Providers 2009/ 2010Organiser: The Hong Kong Medical Association and Our Lady of Maryknoll Hospital, Speaker: Dr. NG Kin Chung, Venue: Training Room II, 1/F., OPD Block, Our Lady of 
Maryknoll Hospital, 118 Shatin Pass Road, Wong Tai Sin, Kowloon, Hong Kong
TUE
Ms. Paulina TANG 
Tel: 2527 8898
Fax: 2865 0345
8:00 pm - 10:00 pm18 FMSHK Executive Committee Meeting  Organiser: The Federation of Medical Societies of Hong Kong, Venue: Council Chambers, 4/F., Duke of Windsor Social Service Building, 15 Hennessy Road, Wanchai, 
Hong Kong 
TUE
Mr. Roget LAW
Tel: 2811 9711
1.5 CME Points for Participant
3 CME Points for Speaker 
1:30 pm 
1:00 pm 
SUN
Ms. Dora HO
Tel: 2527 828530 2nd Seasonal Photo Sharing and Photo CompetitionOrganiser: The Hong Kong Medical Association, Venue: HKMA Head Office, 5/F., Duke of Windsor Social Service Building, 15 Hennessy Road, Wanchai, Hong Kong
Ms. Dora HO
Tel: 2527 8285
HKMA Tenpin Bowling Tournament
Organiser: The Hong Kong Medical Association, Venue: South China Athletic 
Association
2:00 pm 
2:00 pm 
1:30 pm 
6:30 pm - 8:00 pm 
25 HKMA Tai Po Community Network - Common Foot and Ankle ProblemOrganiser: HKMA Tai Po Community Network, Speaker: Dr. CHAN Tun Kut, Venue: Tai Po
SAT
Ms. Teresa LIU / Mr. Patrick WU
Tel: 2528 6618 
Fax: 2866 0616
Email: asm2010@hkcfp.org.hk
(30) 29 HKCFP Annual Scientific Meeting 2010 "Meeting the Challenges of Non-communicable Diseases"Organiser: The Hong Kong College of Family Physicians, Chairman: Dr. CHEUNG Man 
Kuen, Speakers: Various, Venue: HKAM Jockey Club Building, 99 Wong Chuk Hang 
Road, Aberdeen, Hong Kong 
Miss Alice TANG / 
Miss KWONG WL
Tel: 2527 8285/ 2595 6941
HKMA Hong Kong East Community Network - PPI-CME Lecture 2010/2011 on 
"Emergency Medicine"
Organiser: HKMA Hong Kong East Community Network & HA Hong Kong East 
Cluster, Speakers: Dr. WONG Tai Wai & Dr. LI Keung, Venue: HKEC Training Centre 
for Healthcare Management & Clinical Technology, Pamela Youde Nethersole Eastern 
Hospital, Hong Kong 
Date  / Time Function Enquiry / Remarks
VOL.11  NO.5  MAY  2006 Radiology Quiz
    37
L. 5  NO.5  MAY  2010
Dr. WK TSO
Patron
The Honourable
Donald TSANG, GBM ?????
President
Dr. LO See-kit, Raymond ?????
1st Vice-President
Dr. CHAN Chi-fung, Godfrey ?????
2nd Vice-President
Dr. LO Sze-ching, Susanna ?????
Hon. Treasurer
Mr. LEE Cheung-mei, Benjamin ?????
Hon. Secretary
Dr. CHAN Sai-kwing ?????
Executive Committee Members
Dr. CHAN Chi-wing, Timmy ?????
Dr. CHAN Chun-kwong, Jane? ?????
Dr. CHAN Hau-ngai, Kingsley ?????
Dr. CHIM Chor-sang, James ?????
Dr. CHOI Kin ????
Dr. HUNG Che-wai, Terry ?????
Ms. KU Wai-yin, Ellen ?????
Dr. LEUNG Ka-kit, Gilberto ?????
Dr. MAN Chi-wai ?????
Dr. MOK Chun-on ?????
Dr. NG Yin-kwok ?????
Dr. WONG Mo-lin, Maureen ?????
Ms. YAP Woan-tyng, Tina ?????
Dr. YU Chau-leung, Edwin ?????
The Federation of Medical Societies of Hong Kong
4/F Duke of Windsor Social Service Building,
15 Hennessy Road, Wanchai, Hong Kong
Tel: 2527 8898    Fax: 2865 0345
President
Dr. TSE Hung-hing  ?????
Vice- Presidents
Dr. CHAN Yee-shing, Alvin ?????
Dr. CHOW Pak-chin ?????
Hon. Secretary
Dr. LO Chi-fung, Ernie ?????
Hon. Treasurer
Dr. LEUNG Chi-chiu ?????
Council Representatives
Dr. CHAN Yee-shing ?????
Dr. CHOI Kin ????
Chief Executive
Mrs. LEUNG, Yvonne ??????
Tel: 2527 8285 (General Office)
            2527 8324 / 2536 9388  (Club House in Wanchai / Central)
Fax: 2865 0943 (Wanchai), 2536 9398 (Central)
Email: hkma@hkma.org  
Website: http://www.hkma.org
President
Dr. WU, Adrian ?????
Vice-President
Dr. LO See-kit, Raymond ?????
Hon. Secretary
Dr. LI, Anthony ?????
Hon. Treasurer
Dr. LEUNG, Clarence ?????
Council Representatives
Dr. LO See-kit, Raymond ?????
Dr. CHEUNG Tse-ming ?????
Tel:  2527 8898   Fax: 2865 0345
Board of Directors
President
Dr. LO See-kit, Raymond ?????
1st Vice-President
 Dr. CHAN Chi-fung, Godfrey ?????
2nd Vice-President
Dr. LO Sze-ching, Susanna ?????
Hon. Treasurer
Mr. LEE Cheung-mei, Benjamin ?????
Hon. Secretary
Dr. CHAN Sai-kwing ?????
Directors
Mr. CHAN Yan-chi, Samuel ?????
Dr. CHIM Chor-sang, James ?????
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Answer to Radiology Quiz
Chest X-Ray Findings:
Cardiac outline is enlarged. Upper zone blood vessels are 
dilated. Horizontal fissure is slightly thickened. Right 
costophrenic angle is blunted.
The above findings are compatible with congestive cardiac 
failure.
However, an opacity is seen at right lower zone.
Further Investigation:
Lateral CXR which shows a lenticular opacity at the inferior 
part of the oblique fissure.
Diagnosis is loculated effusion at oblique fissure.
Discussion:
Fluid may become loculated in the interlobar fissure. It is not 
common but may occur in cardiac failure. It may be mistaken 
as a lung tumour in the frontal projection. A lateral view will 
usually avoid this mistake. This type of loculated effusion 
may disappear rapidly on treatment and this will confirm 
the diagnosis avoiding any unnecessary investigations. 
These loculated effusions are therefore also known as 
'pseudo-' or 'vanishing' tumours.
Answer:
Chief of Service, Department of Radiology, Queen Mary Hospital

